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ABSTRACT 
 
“CONTROL OF BREAST CANCER CELL GROWTH BY 
ADIPOCYTE-RELEASED FACTORS”  
 
Obesity is one of the most challenging and growing health problems, 
worldwide. Epidemiologic studies now provide compelling evidence that 
obesity is a risk factor for both cancer incidence and mortality. In particular, 
obesity increases rates of breast cancer in postmenopausal women and is 
associated with poorer survival and increased recurrence of disease, regardless 
the menopausal status. It is now becoming clear that adipocytes, which 
represent very abundant cell types surrounding cancer cells, particularly in the 
mammary gland, could influence several aspects of tumorigenesis, from 
promoting local invasion to angiogenesis and metastasis. However, the 
molecular mechanisms involved in the adipocyte control of the malignant 
phenotype remain poorly understood. I have studied the mechanisms by which 
adipocytes may integrate metabolic and nutritional inputs and produce signals 
affecting breast cancer cell phenotypes. I have obtained evidence that 
conditioned media from 3T3-L1 cells induce growth of MCF7 cells, in a time-
dependent manner. In particular, conditioned media from fully differentiated 
adipocytes are 2-fold more effective than conditioned media from pre-
adipocytes in inducing MCF7 growth. Cell cycle analysis by flow cytometry 
revealed that these changes are due to reduced apoptosis instead of increased 
proliferation. Pre-incubation with low glucose medium or insulin reduces the 
effect of adipocyte conditioned media on MCF7 growth. Cytokines/growth 
factors screening of conditioned media from pre-adipoctyte and adipocyte, 
cultured in presence or in absence of low glucose medium or insulin, revealed 
that KC, RANTES and IGF1 could be good candidates in mediating pro-
tumorigenic effect of adipocyte conditioned media. Moreover, IGF1R inhibitor 
AG1024 is able to revert adipocyte conditioned media effect. In conclusion, 
adipocyte-derived factors promote breast cancer cell growth inhibiting the 
apoptosis. This effect is more evident in adipocytes than in pre-adipocytes and 
is altered by insulin or nutritional factors such as glucose. The effects are likely 
mediated by IGF-1.  
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1. BACKGROUND 
 
 
1.1 Obesity 
 
 Overweight and obesity are clinically defined indicators of a disease 
process characterized by the accumulation of body fat due to an excess of 
energy intake (nutritional intake) relative to energy expenditure (physical 
activity). When energy intake exceeds energy expenditure over a prolonged 
period of time, the result is a positive energy balance (PEB), which leads to the 
development of obesity (Fair and Montgomery 2009). 
Several measures are used to define obesity. The most utilized 
parameter is body mass index (BMI, also called Quetelet‘s Index) (weight in 
kilograms divided by height in meters squared), a measure of overall 
overweight status. The World Health Organization (WHO) defined an 
overweight status as a BMI of 25.0 or higher. The overweight category is then 
divided into four categories: preobese, 25.00 to 29.9 kg/m
2
; obese class I, 30.00 
to 34.99 kg/m
2
; obese class II, 35.00 to 39.99 kg/m
2
; and obese class III, ≥ 
40.00 kg/m
2
 (World Health Organization 2000) . 
Obesity is one of the most challenging and growing health problems 
(Van Roermund and Witjes 2007). The prevalence of obesity has reached 
epidemic levels in many parts of the world. Worldwide, more than 1 billion 
adults are overweight (BMI 25) and at least 300 million of them are obese 
(BMI 30) (Fig. 1) (Power et al. 2007). Obesity rates are slightly higher in 
men, and increase from youth to middle age (Moayyedi 2008). In the United 
States, 59 million adults (31%) are obese and 4.7% are considered morbidly 
obese (BMI ≥ 40) (Power et al. 2007). The situation in Europe is somewhat 
better. The prevalence of adult obesity in the states of EU is lower than in the 
USA: in males between 8-25%, in females between 8-27%. The highest obesity 
prevalence is in Central Europe, especially in the Czech Republic and in 
England (Ginter and Simko 2008). The problem is not restricted to 
industrialized societies: obesity rates are increasing in urban areas of 
developing countries, particularly those in transition. Of special concern are the 
increasing numbers of overweight children and adolescents in many countries 
(Aranceta et al. 2009). 
It is clear from family, twin, and adoption studies that genetic factors 
contribute to the obesity phenotype. Such studies, conducted in countries where 
food is plentiful, suggest that 40–70% of individual variability in body mass in 
these settings may be explained by hereditable factors (Calle and Thun 2004).  
Genes that influence energy balance in humans may operate through multiple 
central and peripheral homeostatic pathways that influence caloric intake, 
expenditure, and/or storage. Energy balance is mediated through endocrine and 
neural signals coming from a variety of peripheral tissues to the central nervous 
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system. Afferent signals received in the hypothalamus modulate the release of 
peptides and generate efferent signals that regulate energy expenditure 
(through the sympathetic and parasympathetic nervous systems and thyroid 
hormones) and energy intake. Genes and proteins that play a role in common 
obesity may regulate appetite and satiety (e.g. cholecystokin, neuropeptide Y, 
melanocortins, leptin), insulin sensitivity and glucose metabolism in muscle 
and other peripheral tissues (e.g. insulin and insulin receptor), and energy 
storage and expenditure in adipose tissue (e.g. lipoprotein lipase) (Calle and 
Thun 2004). 
Over 200 association studies have been conducted relating genetic 
variation in candidate genes to obesity phenotypes. These studies generally 
have observed small, uncertain, or inconsistent effects. Significant positive 
associations have been observed in five or more studies for about 15 genes, 
including common polymorphisms in the beta-adrenergic receptors ( -AR2, -
AR3), the peroxisome proliferator- activated receptor gamma (PPAR ), LEP, 
LEPR, uncoupling protein genes (UCP-1, UCP-2, and UCP-3), and tumor 
necrosis factor alpha (TNF ) (Chagnon et al. 2003). 
 
Fig. 1: Prevalence of overweight worldwide (BMI>25) 
 
While single gene mutations rarely account for obesity in humans, it is 
likely that obesity is influenced by the interaction of multiple genes, each with 
modest effects, and further interactions with environmental factors such as 
energy availability, physical activity, and smoking (Calle and Thun 2004).  
It should be noted that genetic and biologic determinants of obesity 
only become manifest in social environments that provide abundant calorie-
dense foods and facilitate physical inactivity. Genetic factors predispose 
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individuals to gain weight. Only environmental factors cause sudden large 
shifts in the prevalence of obesity in populations. An obesogenic environment 
is probably the primary cause of the recent trends in obesity (Aranceta et al. 
2009). 
There is consistent evidence that obesity is associated with an increase 
in all cause mortality, and in the United States obesity is estimated to cause 
over 100,000 excess deaths annually. The mean loss of life years attributed to 
obesity is at least 2 years, and in young men this figure could be as high as 10–
20 years. The effects of obesity are more marked in men, and there are racial 
differences, although obesity is associated with reduced life expectancy in all 
ethnic groups. The impact of obesity on mortality is less in subgroups where 
the competing causes of death are increased, such as the elderly and smokers 
(Moayyedi 2008).  
There are a variety of diseases associated with obesity that contribute to excess 
mortality. Obesity has long been recognized to be an important cause of type II 
diabetes mellitus, hypertension, and dyslipidemia (National Task Force on the 
Prevention and Treatment of Obesity 2000). Cohort studies suggest more than 
a 10- to 20-fold increase in risk of developing diabetes in those with a BMI 
≥35 kg/m2 (Field et al. 2001). The adverse metabolic effects of excess body fat 
are known to accelerate atherogenesis and increase the risk of coronary heart 
disease, stroke, and early death. Obesity is also predictive of diseases that 
cause serious morbidity, such as osteoarthritis  and sleep apnea, and is linked to 
an increase in hospital admissions (Calle and Thun 2004; Moayyedi 2008). 
There are also considerable psychosocial consequences of obesity (Ginter and 
Simko 2008). 
Moreover, epidemiologic studies provide sufficient evidence that 
obesity is a risk factor for both cancer incidence and mortality (Pan and 
DesMeules 2009). 
 
 
1.2 Epidemiologic studies of obesity and cancer 
 
The available literature on weight and cancer has contributed to the 
knowledge that a PEB or obese status is related to elevated cancer risk (Malin 
et al. 2005). The association of overweight and obesity with noncancer 
outcomes is generally stronger than the association with all cancer or specific 
cancer sites (Calle and Thun 2004). Moreover, a meta-analysis suggested that, 
in Europe, 72,000 cancer cases each year could be attributed to an excess body 
mass (Bergström et al. 2001). 
The International Agency for Research on Cancer (IARC) Working 
Group on the Evaluation of Cancer Preventive Strategies recently published a 
comprehensive evaluation of the available literature on weight and cancer that 
considered epidemiologic, clinical, and experimental data. Their report 
concluded that  the avoidance of weight gain reduces the risk of developing 
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cancers of the colon, breast (in postmenopausal women), endometrium, kidney 
(renal cell), and esophagus (adenocarcinoma) (IARC 2002). These conclusions 
are based on epidemiologic studies of overweight and/or obese individuals 
compared to leaner individuals, not on studies of individuals who have lost 
weight. Unfortunately, few individuals lose and maintain significant amounts 
of weight, making it extremely difficult to examine cancer outcomes in large 
populations of weight losers. Consequently, the IARC report concluded that 
there is inadequate evidence in humans for a cancer-preventive effect of 
intentional weight loss for any cancer site. An association between overweight 
and obesity and cancer at many sites is consistent with animal studies showing 
that caloric restriction dramatically decreases spontaneous and carcinogen-
induced tumor incidence, multiplicity, and size (Calle and Kaaks 2004). 
 
 
Tab 1: Obesity-related cancers 
Relative risks (RRs) associated with overweight and obesity, and the percentage of cases 
attributable to overweight and obesity in the USA . BMI , body mass index; ND , not 
determined; EU , European Union; PAF , population attributable fraction.. b Data on 
prevalence of overweight and obesity are from the National Health and Nutrition Examination 
Survey (1999 – 2000)  for men and women from the United States aged from 50 to 69 years. c 
Data on prevalence of overweight and obesity are from a range of sources  of adult men and 
women residing in 15 European countries in the 1980s and 1990s. d PAFs were not estimated 
because the magnitude of the RRs across studies are not sufficiently consistent. 
 
 
The literature on the relationship between body size and the colon and 
rectal cancers has demonstrated a positive association between risk of 
colorectal cancer and body fat distribution as indicated by BMI. Studies that 
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have examined association with obesity (BMI > 30.0 kg/m
2
) found nearly 
twice the risk for colorectal cancer compared with those reporting association 
for overweight status or a BMI of over. The risk of colon cancer in men with a 
BMI > 30 increased up to 80%. Obesity has been consistently associated with 
higher risk of colorectal cancer in men (RRs, ~1.5 – 2.0) and women (RRs, 
~1.2 – 1.5) in both case-control and cohort studies (Tab. 1).  
Endometrial cancer (cancer of the uterine lining) was the first cancer to 
be recognized as being related to obesity. A linear increase in the risk of 
endometrial cancer with increasing weight or BMI has been observed in most 
studies ranging from twofold to fivefold in overweight and/or obese women 
(Tab. 1) (Fair and Montgomery 2009).  
Studies of population worldwide have revealed that the risk of kidney 
cancer (specifically, renal-cell cancer) is 1.5-3 times higher in overweight and 
obese individuals than in normal weight men and women (Tab. 1). Most 
studies reported a dose- response relationship with increasing weight or BMI 
(Calle and Kaaks 2004). 
Obesity is associated with a two- to threefold increase in risk for 
adenocarcinoma of the esophagus  with stronger associations seen in 
nonsmokers (Tab. 1) (Hoyo and Gammon 2006). 
There have been few previous studies of gall bladder cancer and 
obesity, and most have been relatively small (Tab. 1). Available studies have 
consistently found elevated risks for women (of about twofold), but generally 
have had too few cases to evaluate the association in men (Calle and Kaaks 
2004). 
Several recent studies have suggested that high body mass may be 
associated with approximately a doubling of risk for pancreatic cancer in men 
and women. However, smaller, earlier studies did not support an association 
and further research is needed (Berrington de Gonzalez et al. 2003).  
Few studies have investigated the association of body mass with 
cancers of the liver, stomach, uterine cervix, and hematopoietic system. Three 
studies that have examined obesity and liver cancer found excess relative risk 
in both men and women in the range of 2.0–4.0. Importantly, obesity has been 
consistently shown to increase rates of breast cancer in postmenopausal women 
by 30 – 50% (Tab. 1) (Calle and Kaaks 2004).  
 
 
1.3  Obesity and breast cancer 
 
Breast cancer is the most commonly diagnosed cancer in the female 
population and is second in cancer related deaths in the United States. While 
the mortality has decreased slightly in recent years, the number of cases 
diagnosed annually has remained relatively steady. According to the American 
Cancer Society, over 178000 new cases are diagnosed each year, with an 
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estimated 40 400 deaths from breast cancer in 2008. Five year survival rates of 
breast cancer patients is almost 90%, although higher in patients over 40, as 
women diagnosed at a young age typically have amore aggressive cancer that 
is less responsive to treatment. Though both incidence rates and mortality rates 
have decreased in recent years, the healthcare costs and the emotional costs of 
breast cancer remain high (Jemal et al. 2008). 
 A number of risk factors are associated with development of breast 
cancer. The greatest risk factors are age and gender, with females developing 
breast cancer 100 times more frequently than males. As a woman ages, her risk 
of developing breast cancer increases, from 1 in 233 between the ages of 30–39 
to 1 in 27 between the ages of 60–69. While age and gender are the greatest 
risk factors, there are also hormonal risk factors associated with breast cancer 
development, including age at first menarche, age at menopause, and lifetime 
exposure to estrogen. Furthermore, a family history of breast cancer and a 
history of previous benign breast disease are risk factors associated with breast 
cancer. Interestingly, some risk factors are modifiable, such as diet and obesity 
(Carter and Church 2009).  
Many epidemiologic studies since the 1970s have assessed the 
association between anthropometric measures and breast cancer occurrence 
and/or prognosis (Stephenson and Rose 2003). Early studies established that 
the association between body size and risk of breast cancer differed according 
to menopausal status, and that heavier women were at increased risk of 
postmenopausal, but not premenopausal breast cancer. In fact, among 
premenopausal women, there is consistent evidence of a modest reduction in 
risk among women with high (≥28) BMI (IARC 2002).  
Obesity has been shown consistently to increase rates of breast cancer 
in postmenopausal women by 30–50% (tab. 1). Some studies have found 
central adiposity to be an independent predictor of postmenopausal breast 
cancer risk beyond the risk attributed to overweight alone. In addition, adult 
weight gain has generally been associated with a larger increase in risk of 
postmenopausal breast cancer than has BMI, in studies that examined both 
(Calle and Thun 2004). 
Studies of breast cancer mortality and survival among breast cancer 
cases illustrate that adiposity is associated both with poorer survival and 
increased likelihood of recurrence among those with the disease, regardless of 
menopausal status and after adjustment for stage and treatment. Very obese 
women (BMI ≥40.0) have breast cancer death rates that are three times higher 
than very lean (BMI ≤20.5) women. The greater risk of death among heavier 
women likely reflects both a true biological effect of adiposity on survival and 
delayed diagnosis in heavier women (Petrelli et al. 2002). 
The mechanism behind the relationship of increased incidences of 
breast cancer in obese individuals is poorly understood; however, the literature 
concerning this association has increased in recent years (Carter and Church 
2009).  
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The breast is a very heterogeneous tissue, composed of a number of 
different cell types. Epithelial cells make up the parenchyma of the tissue, 
forming the ducts and glands involved in milk production, storage, and 
secretion. Surrounding these epithelial cells is a network of fibroblasts, which 
generate the proteins of the breast connective tissue. Another key component of 
breast tissue is adipose, composed of mesenchymal precursor cells and the 
mature adipocytes (Crum et al. 2003). 
The tumor microenvironment provides a number of signals and 
resources to the tumor cells, promoting proliferation, survival, and motility. In 
that regard, adipocytes, or their precursor cells, may provide key factors in 
breast tissue needed for tumor development, progression, or even enable tumor 
cell invasion. Collectively, these results imply that excess amounts of adipose 
in either the breast or other distant fat depots could provide a climate amenable 
to development of carcinoma of the breast (Carter and Church 2009).  
 
 
1.4 Adipose tissue 
 
Adipose tissue, commonly called ‗fat‘, is a type of loose connective 
tissue comprised of lipid-filled cells (adipocytes) surrounded by a matrix of 
collagen fibers, blood vessels, fibroblasts and immune cells. In certain areas, 
for example, subcutaneous and mesentery regions, adipose tissue is organized 
into large lobular structures (Ahima and Flier 2000). Adipose tissue itself is 
composed of not only adipocytes but also by other cell types found in the 
stroma-vascular fraction, which include macrophages, fibroblasts, pericytes, 
blood cells, endothelial cells, and adipose precursor cells, among others (Fig. 
2) (Frühbeck 2008). 
White adipose tissue, the predominant type of adipose tissue in humans, 
is characterized by adipocytes with a single lipid inclusion and eccentrically 
located nucleus (Ahima and Flier 2000).  
White adipose tissue has long been recognized as the main site of 
storage of excess energy derived from food intake. White adipocytes store 
dietary energy in a highly concentrated form as triglyceride, mostly in a single 
large lipid droplet. These structures are associated with a unique complement 
of proteins, which enable the sequestration or mobilization of lipids. In times of 
caloric need, these triglycerides can be rapidly hydrolysed by lipases (a process 
known as lipolysis) and the resulting fatty acids are transported to other tissues 
to be oxidized in mitochondria as an energy source. By contrast, brown fat is 
specialized primarily for non-shivering thermogenesis, a cold climate 
adaptation in many homeotherms. Brown adipocytes are characterized by 
multiple, smaller droplets of triglyceride, which are accessible for rapid 
hydrolysis and rapid oxidation of the fatty acids. Brown fat depots are present 
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in human infants and recent evidence suggests that dispersed brown adipocytes 
might persist in adults (Guilherme et al. 2008). 
 
Fig. 2: Schematic representation of the multicellularity of adipose tissue with 
approximate quantitative contribution of adipocytes compared to the stromavascular 
fraction  
 
White adipose tissue is actively involved in cell function regulation through a 
complex network of endocrine, paracrine, and autocrine signals that influence 
the response of many tissues, including the hypothalamus, pancreas, liver, 
skeletal muscle, kidneys, endothelium, and immune system, among others. 
Furthermore, adipocytes are uniquely equipped to participate in the regulation 
of other functions such as reproduction, immune response, blood pressure 
control, coagulation, fibrinolysis, and angiogenesis, among others (Fig. 3) 
(Schäffler 2006).  
The identification of adipose tissue as a multifunctional organ has been 
brought about by the emerging body of evidence gathered during the last 
decades, which opposes the static view of adipose tissue as a merely passive 
organ devoted to the storage of excess energy in the form of fat. This 
pleiotropic nature is based on the ability of fat cells to secrete a large number 
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of hormones, growth factors, enzymes, cytokines, complement factors, and 
matrix proteins, collectively termed as adipokines or adipocytokines (Fig. 4), at 
the same time as expressing receptors for most of these factors, which warrants 
an extensive crosstalk at a local and systemic level in response to specific 
external stimuli or metabolic changes. The vast majority of adipocyte-derived 
factors have been shown to be dysregulated in the alterations accompanying 
adipose tissue mass changes (Frühbeck 2008). 
 
Fig. 3: Dynamic view of white adipose tissue based on the pleiotropic effects exerted on 
quite diverse organs and their respective physiological functions 
 
It is now evident that adipose tissue is the source of production of a 
multiplicity of secretory factors, which vary considerably in terms of structure, 
function, and cellular origin. For instance, classical cytokines include TNF-α 
and interleukin-1, 6, 10, and 18 (IL-1, IL-6, IL-10, IL-18), whereas monocyte 
chemoattractant protein-1 (MCP-1), macrophage migration inhibitory factor 
(MIF), and IL-8 belong more to the subgroup of chemokines. The diversity of 
secreted molecules includes also factors involved in lipid and glucose 
metabolism such as lipoprotein lipase (LPL), apolipoprotein E (apoE), 
cholesteryl ester transfer protein, PPAR, glucocorticoids, sex steroids, 
prostaglandins, adipsin, acylation stimulating protein, leptin, resistin, 
adiponectin/Acrp30/adipoQ, osteonectin, and cathepsins, among others. 
Finally, secreted growth factors include insulin-like growth factor 1 (IGF1), 
nerve growth factor (NGF), macrophage colony-stimulating factor, 
transforming growth factor-β (TGF-β), vascular endothelial growth factor 
(VEGF), heparin-binding epidermal growth factor, leukemia inhibitory factor, 
and bone morphogenetic proteins (Fruhbeck 2008). 
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The adipocyte is therefore an excellent candidate cell to play an 
important role in influencing tumor behavior through heterotypic signaling 
processes and may prove to be critical for tumor survival, growth, and 
metastasis in the breast. However, it  is not known how adipocytes influence 
breast tumor cell behavior or whether any of the paracrine factors secreted by 
adipocytes cause changes in the phenotypic behavior of the malignant cells 
(Iyengar et al. 2003). 
 
 
Fig. 4: Diagram of the multiple adipose-derived factors 
 
 
1.5 Proposed mechanisms relating adiposity to cancer risk 
 
The biological mechanisms that link overweight and obesity to many forms 
of cancer are poorly understood. Obesity-associated changes in hormone 
metabolism (insulin, insulin-like growth factor1, sex steroids), in adipocyte-
released factors and in inflammatory response may contribute to tumorigenesis, 
tumor progression and metastatic potential (Calle and Kaaks 2004, Harvie and 
Howell 2006). 
 
 Endogenous hormones: Insulin, IGF1 and sex steroids 
The association between excess body weight with cancer risk may be 
explained by alterations in the metabolism of endogenous hormones – 
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including insulin, insulin-like growth factors and sex steroids – which can lead 
to distortion of the normal balance between cell proliferation, differentiation, 
and apoptosis. However, the pathophysiological and biological mechanisms 
underpinning these associations are only starting to be understood (Osório-
Costa et al. 2009).  
Excess body weight, increased plasma triglyceride levels, low levels of 
physical activity and certain dietary patterns can all favor elevated circulating 
insulin levels. In the early 1990's, McKeown-Eyssen (1994) and Giovannucci 
(1995) noted that the risk factors for Westernized cancer were remarkably 
similar to those for insulin resistance, and suggested that hyperinsulinemia 
might contribute to cancer development through the growth-promoting effect 
of elevated levels of insulin. In addition to its importance in glucose 
homeostasis, it is well established that insulin is a crucial hormone in anabolic 
processes involved in early growth and development, and may be also a strong 
mediator of the adverse effect of obesity on cancer prognosis (Osório-Costa et 
al. 2009).  
Chronically increased insulin levels have been associated with colon cancer 
pathogenesis and with cancers of the breast, pancreas and endometrium. These 
tumorigenic effects of insulin could be directly mediated by insulin receptors in 
the (pre) neoplastic target cells, or might be due to related changes in 
endogenous hormone metabolism, secondary to hyperinsulinemia. For 
example, insulin has effect on the synthesis and biological availability of 
insulin-like growth factor 1 and sex hormones including androgens, 
progesterone and oestrogens (Calle and Kaaks 2004). 
The IGF1 is a peptide hormone with a molecular structure very similar to 
that of insulin. The principal stimulus for the synthesis of IGF1 in liver, which 
is the source of over 80% of circulating IGF1, is provided by Growth Hormone 
(GH). Nutritional energy balance can have profound effects on its synthesis 
and biological activity (Pollak et al. 2004; Kaaks and Lukanova 2001).  
IGF1 plays an important role in regulating cell proliferation,
 
differentiation, 
apoptosis, and transformation. 
IGF1 exert
 
its actions by interacting with a specific receptor on the
 
cell 
membrane, namely, the IGF1 receptor (IGF-1R), and the
 
interaction is 
regulated by a group of specific binding proteins (IGFBP) (Yu and Rohan 
2000). At least 75% of IGF1 in the circulation is bound to IGFBP3, whereas 
most of the remainder is bound to at least five additional binding proteins 
(IGFBP1, IGFBP2, IGFBP4, IGFBP5 and IGFBP6). The IGFBPs have many 
functions, including the stabilization of a large pool of IGF1 in the circulation 
and the regulation of the availability of IGF1 for binding to its receptor 
(Clemmons 1998), in particular, IGFBP-1 is considered the chief acute 
regulator of IGF1 bioactivity (Harvie and Howell 2006). 
Recently, a number of epidemiologic studies have
 
shown consistently that 
high circulating levels of IGF1, are associated
 
with increased risk for several 
common cancers, including those
 
of the breast, prostate, lung, and colorectum 
(LeRoith and Helman 2004).
 
These findings were confirmed in animal models, 
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where reduced circulating IGF1 levels result in significant reductions in cancer 
development, growth, and metastases, whereas increased circulating IGF1 
levels are associated with enhanced tumor growth (Wu et al. 2003).  
Aberrant expression of the IGF-1R has been implicated in malignant 
transformation of cells. IGF-1R is normally activated by binding of the 
secreted growth factor ligand to the extracellular domain. This, in turn, triggers 
a number of cellular signalling pathways, including the phosphatidylinositol 3-
kinase (PI3K) pathway, the main mechanism by which IGF-1R protects cells 
from apoptosis (Alberobello et al.).  
There are also several lines of evidence that dysregulation of the IGF1 
system is involved in resistance to certain anticancer therapies, including 
cytotoxic chemotherapy, hormonal agents, biological therapies, and radiation 
(Ryan and Goss 2008).   
Finally, it has been shown that the level of IGFBP3, a major IGF1-binding
 
protein in serum that, in most situations, suppresses the mitogenic
 
action of 
IGF1, is inversely associated with the risk of these
 
cancer (Yu and Rohan 
2000). 
 
 
Fig. 5: Effect of obesity on growth factor and hormone production.  
Obesity leads to hyperinsulinemia, which in turn causes a reduction in IGFBP and SHBP 
synthesis. This results in increased levels of bioavailable IGF1, E2 and T. Insulin and IGF1 
signal through the insulin receptors (IRs) and IGF1 receptor (IGF1R), respectively, to promote 
cellular proliferation and inhibit apoptosis in many tissue types. E2 and T can diffuse to target 
cells, where they bind to oestrogen and androgen receptors. The effects of sex steroids binding 
their receptors can vary, depending on the tissue types, but in some tissues (for example, breast 
epithelium and endometrium) they promote cellular proliferation and inhibit apoptosis. 
Adapted from Calle and Kaaks (2004). 
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Chronically increased insulin concentrations lead to reduced liver synthesis 
and blood levels of IGFBP1, and probably also reduce IGFBP1 synthesis 
locally in other tissues. Increased fasting levels of insulin in the plasma are 
generally also associated with reduced levels of IGFBP2 in the blood. This 
results in increased levels of free bioavailable IGF1 and concomitant changes 
in the cellular environment, that favor tumor development (Fig. 5). It is also 
suggested that IGF1 can synergize with other growth factors to produce 
enhanced mitogenic effects, and may operate via an endocrine, paracrine or 
autocrine manner to regulate cell growth, cell survival, cell transformation, and 
cell differentiation (Calle and Kaaks 2004; Osório-Costa et al. 2009).  
With regard to sex steroids, adiposity influences the synthesis and 
bioavailability of the hormones — the oestrogens, the androgens and 
progesterone — through at least three mechanisms. First, adipose tissue 
expresses a variety of sex-steroid-metabolizing enzymes, like aromatase, that 
promote the formation of estrogens from androgenic precursors, which are 
secreted by the gonads or adrenal glands. Adipose tissue is the major site of 
estrogen synthesis in men and postmenopausal women, with levels of 
aromatase and circulating levels of estrone and estradiol strongly related to 
BMI. A second hypothesis is that obesity results in an increase in circulating 
levels of insulin and IGF1 bioactivity. Insulin and IGF1 both inhibit the 
synthesis of sex hormone-binding globulin (SHBG) – the major carrier protein 
for testosterone and estradiol in the plasma – and may lead to an increase in the 
amount of unbound sex-steroid available for bioactivity (Fig. 5). In women, 
decreases in SHBG generally also lead to increased levels of bioavailable 
testosterone. In men, by contrast, decreases in SHBG generally lead to 
reductions in total testicular testosterone production, and no increase in 
bioavailable testosterone. The combined effect of increased formation of 
oestrone and testosterone, along with reduced levels of SHBG, leads to an 
increase in the bioavailable fractions of E2 and T that can diffuse to target 
cells, where they bind to oestrogen and androgen receptors. The effects of sex 
steroids binding their receptors can vary, depending on the tissue types, but in 
some tissues (for example, breast epithelium and endometrium) they promote 
cellular proliferation and inhibit apoptosis. Finally, high insulin levels can 
increase ovarian, and possibly also adrenal, androgen synthesis, and can cause 
the development of the polycystic ovary syndrome in some genetically 
susceptible pre-menopausal women (Calle and Kaaks 2004). 
 
 
 Adipocyte released factors: adipokines and inflammatory cytokines 
 
Current epidemiologic and experimental studies of the obesity-cancer 
association focus on the role of increased adipose tissue, particularly the 
increase in circulating adipocyte-derived factors (adipokines). 
Multiple factors from adipose tissue, such as leptin, adiponectin, cytokines, 
and other secreted products,  including growth factors, hormone-like 
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molecules, acute phase reactants, complement-related proteins, and 
extracellular matrix proteins, influence processes involved in carcinogenesis. In 
addition, reduction of adiposity by calorie restriction or physical activity 
suppresses tumor development and lowers circulating levels of many 
adipokines, further implicating them in tumor development. (Nunez et al. 2006; 
Iyengar et al. 2003). 
Adipocytokines were shown to participate to some extent in the process of 
carcinogenesis, however most if not all of these positive data come from in 
vitro studies on cancer cell lines.  
Leptin, the most widely studied member of a family, is a multifunctional 
neuroendocrine protein with wide ranging biological activities including 
appetite regulation, bone formation and reproductive function and 
angiogenesis. It stimulates growth, migration and invasion of cancer cells in 
vitro and also potentiates angiogenesis, thus displaying a capacity for 
promoting malignant biological behavior of cancer in vitro (Housa et al. 2006; 
Rose et al. 2004).  
Adiponectin is one of the most studied adipokines with a high expression 
level in adipose cells and with high concentrations in serum. It is exclusively 
secreted by the adipose cells and exerts many different effects in obesity-
related disorders. Much remains to be learnt about its physiological functions, 
but evidence is accumulating for a role in the inhibition of inflammatory 
processes, modulation of endothelial function, and protection against the 
consequences of the insulin resistance syndrome. Also, in contrast to other 
adipocytokines, adiponectin has been reported to suppress angiogenesis by a 
process which involves activation of members of the caspase group of 
apoptotic enzymes (Andersson et al. 2008; Rose et al. 2004). Although there 
have been no studies of the effect of adiponectin on proliferation of normal 
breast or breast cancer cells, a recent in vitro study showed adiponectin to be a 
potent inhibitor of endothelial cell proliferation and primary tumour growth of 
a sarcoma mouse model via inhibition of angiogenesis. Two medium-sized 
case–control studies demonstrated significant inverse associations between 
circulating adiponectin and breast cancer (Harvie and Howell 2006).  
VEGF, HGF and IGF1 are not usually found on a list of the 
adipocytokines, but they are produced by adipose cells, where they have 
important functions.  
VEGF has a critical role in the angiogenic process, being a specific 
mitogen for vascular endothelial cells; it also promotes angiogenesis by 
inducing matrix metalloproteinase (MMP) expression, and stimulating vascular 
endothelial cell migration .  
Like VEGF, HGF stimulates vascular endothelial cell proliferation and 
migration in vitro, induces MMP expression, and stimulates angiogenesis in in 
vivo models (Rose et al. 2004). Several investigations have shown that the 
serum concentrations of HGF are often elevated in breast cancer patients, and 
particularly so in those with advanced disease (Vona-Davis and Rose 2007). 
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 Until now, the role of IGF1 signaling in white adipose tissue has remained 
unclear.  In vitro IGF1 is an essential regulator of differentiation, and it was 
recently shown that IGF-1 stimulates both cell growth and lipogenesis during 
differentiation of human mesenchymal stem cells into adipocytes in vitro. 
However, the physiological role of IGF1 signaling in adipose tissue in vivo has 
not been systematically studied (Klöting et al. 2008). 
Inflammation has also been implicated in obesity and tumorigenesis, it  is 
thought to underlie some of the cancer effects of excess adiposity (Nunez et al. 
2006; Harvie and Howell 2006). Inflammation has been linked to risk of breast 
and other obesity related cancers such as colorectal cancer (Harvie and Howell 
2006). Indeed, the consistent results from epidemiologic studies linking 
adiposity and the risk of several adult cancers turns plausible the hypothesis 
that the molecular mechanisms of carcinogenesis may be mediated by 
inflammatory pathways (Osório-Costa et al. 2009), however the mechanism by 
which it happens is not yet known. 
 Adipose tissue produces and secretes a lot of inflammatory cytokines, for 
example TNF  and IL-6. Cytokine expression and plasma levels increase in 
proportion to adiposity and as a result of changes in energy balance. An 
increasing number of immune mediators produced from adipocytes found in 
adipose tissues are being identified (Fair and Montgomery 2009). 
TNF  is a pro-inflammatory cytokine which can inhibit tumour cell 
proliferation  and promote cellular apoptosis, but also stimulates oestrogen 
biosynthesis by way of aromatase induction, and angiogenesis. Under 
physiological conditions, TNF  is produced in adipose tissue in relatively large 
quantities. However, the TNF  derived from adipose tissue originates only in 
part from the adipocytes; a considerable portion may be secreted by infiltrating 
macrophages, and particularly so in obesity (Rose et al. 2004). In obese 
adipose tissue, infact, there is macrophage recruitment, which, in turn, results 
in a pro-inflammatory state. Macrophages that are infiltrated in other tissues 
are known to secrete large amount of TNF, leading to a chronic inflammatory 
state with impaired triglyceride deposition and increased lipolysis, the excess 
of circulating triglyceride and free fatty acids results in disruption of normal 
metabolic functions such as mitochondrial oxidative phosphorylation and 
insulin-stimulated glucose transport (Osório-Costa et al. 2009). TNF  has been 
reported to stimulate angiogenesis in in vivo models.  
Also the other main pro-inflammatory cytokine, IL-6, has activities related 
to insulin resistance, angiogenesis, and tumour cell biology. Like leptin and 
TNF , IL-6 can stimulate oestrogen biosynthesis by the induction of aromatase 
activity. Human adipocytes secrete sizeable amounts of IL-6. In vitro, IL-6 
stimulated invasion of a metastatic human breast cancer cell line, and in breast 
cancer patients elevated serum IL-6 levels were associated with aggressively 
metastatic disease (Rose et al. 2004). 
  
25 
 
2. AIM OF THE STUDY 
 
Since the 1980‘s, the world has been living a striking increase in the 
prevalence of overweight and obesity. This phenomenon has had its beginning 
in developed countries, but, nowadays, it is also common to many other 
populous regions over the world, as Asia and Latin America, and it is 
becoming a Public Health concern (Osório-Costa et al. 2009). Since obesity 
has long been recognized as an important cause of diabetes and cardiovascular 
diseases, the relationship between obesity and different types of cancer has 
received less attention than its cardiovascular effects. Results from 
epidemiological studies that largely began in the 1970s indicate that adiposity 
contributes to the increased incidence and/or death from cancers of the colon, 
breast (in postmenopausal women), endometrium, kidney (renal cell), 
oesophagus (adenocarcinoma), gastric cardia, pancreas, gallbladder and liver, 
and possibly other cancers. It has been estimated hat 15–20% of all cancer 
deaths in the United States can be attributed to overweight and obesity. As the 
worldwide obesity epidemic has shown no signs of abating, insight into the 
mechanisms by which obesity contributes to tumour formation and progression 
is urgently needed, as are new approaches to intervene in this process (Calle 
and Kaaks 2004) 
Current epidemiologic and experimental studies of the obesity-cancer 
association focus on the role of increased adipose tissue, particularly the 
increase in circulating adipocyte-derived factors (Nunez et al. 2006). 
Adipocyte represents one of the most abundant cell types surrounding 
cancer cells and could influence several aspects of tumorigenesis, from 
promoting local invasion to angiogenesis and metastasis to distant sites that are 
fat enriched (such as the bone marrow). In fact, adipose tissue expresses and 
secretes a variety of adipokines and proinflammatory cytokines, but also 
extracellular matrix proteins, complement and coagulant-related proteins, acute 
phase reactants, tissue factors and different growth factors such as vascular 
endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and 
insulin-like growth factor 1 (IGF1) (Iyengar et al. 2003, Klöting et al. 2008; 
Ahima and Flier 2000). All of these factors may be envisioned as contributing 
factors for cancer onset and/or progression (Feldmann 2008). In addition, 
reduction of adiposity by calorie restriction or physical activity suppresses 
tumor development and lowers circulating levels of many adipokines, further 
implicating them in tumor development (Nunez et al. 2006). 
The aim of this study is to identify the molecular mechanisms by which 
adipocytes control breast cancer cells growth. Indeed, adipose tissue is a highly 
relevant component of the mammary gland and may influence the function of 
mammary epithelial cells (Hovey et al. 1999). In particular, the work aims to 
demonstrate that metabolic perturbations affect the production/secretion of 
adipocyte factors (adipokines, inflammatory cytokines and growth factors) 
potentially involved in cancer cell growth control.  
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3. MATERIALS AND METHODS 
 
3.1 Cell culture  
 
The MCF-7 human breast cancer cells and 3T3-L1 murine fibroblast 
cells were available in host laboratory. They were grown in Dulbecco‘s 
modified Eagle‘s medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 100 IU/ml penicillin, 100 IU/ml streptomycin, and 2% L-
glutamine in a 5% humidified CO2 incubator. 3T3-L1 cells were differentiated 
as previously described (Engelman et al. 1998). In brief, after 2 days from 
confluence (Day 0), the DMEM 10% FBS was changed and new DMEM 10% 
FBS was added to the cells with the addition of 160 nm insulin, 250 nm 
dexamethasone, and 0.5mm 3-isobutyl-1-methylxanthine. After 2 days (Day 2), 
this medium was replaced with fresh DMEM 10% FBS containing only 160 
nm insulin. After another 2 days, the cells were then propagated in only 10% 
FBS medium. Adipogenesis was scored by analysis of the expression of 
adipocyte-specific genes (aP2 and peroxisome proliferator-activated receptor γ 
(PPARγ)) (Chavey et al. 2003) and by lipid accumulation using microscopic 
analysis or oil red O staining (Ramirez-Zacarias et al. 1992). Human adipose 
tissue was digested with collagenase as previously reported (Rotter et al. 2003) 
and incubated in Minimum Essential Medium (MEM) supplemented with 1% 
human albumin. 
 
 
3.2 Conditioned media system 
 
The conditioned media was isolated in the following way: confluent 
3T3-L1 adipocyte or 3T3-L1 fibroblast plates were identified, the 10% FBS 
removed, the plates washed two times with sterile phosphate-buffered saline 
(PBS), and 3–5 ml of serum-free DMEM 0,25%BSA (DMEM-BSA) added to 
the plates and incubated for approximately 8h. After the incubation, the 
DMEM-BSA was collected and centrifuged at 14000xg to remove cellular 
debris. The centrifuged conditioned media was then placed on MCF-7 cells for 
variable periods of time as indicated in the respective experiments. Often, to 
prevent the treated MCF-7 cells from becoming sick due to harmful 
metabolites that may have leached into the DME-BSA, low levels of serum 
(0.1% FBS) were added to the conditioned media (protective agent). This small 
amount of serum was added across all samples.  
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3.3 Cell proliferation assay 
 
MCF-7 cells were seeded in 6-well culture plates  at a concentration of 
1 · 10
5
 cells/well in a complete medium. The following day, the cells were 
refed with serum-free DMEM 0,25%BSA for 16h in an atmosphere of 5% 
CO2. Then, the cells were incubate with conditioned media for different times, 
trypsinized and centrifuged, and cell pellets were resuspended in PBS. Cell 
count was performed by Bürker chamber. Three replicate wells were used for 
each data point, and the experiment was performed three times. 
 
 
3.4 Flow cytometry 
 
Cells were fixed with ethanol and routinely kept at -20°C overnight. For 
analysis, cells were centrifuged, resuspended in PBS containing 0.1mg/ml 
RNaseA and 40 g/ml propidium iodide and incubated in dark for 30 min at 
room temperature. Samples were kept on ice and the analysis was performed 
using FACS Cyan cytometer (Dako Cytomation, USA). A minimum of 30000 
events were collected for each sample. Sub-G1 phase cells were identified 
using Summit V 4.3 software (Dako). 
 
 
3.5 Western Blot analysis  
 
MCF7 were lysed in lysis buffer (50mM HEPES pH 7.6, 150mM NaCl, 
10mM EDTA, 10mM Na4P2O7, 2mM Na3VO4, 100mM NaF, 10% glycerol, 
1mM PMSF, 100 IU/ml aprotinin, 20 M leupetin, 1% Triton X-100), for 2 h at 
4 °C and lysates were centrifuged at 14,000 x g for 15 minutes to remove 
cellular debris. Cell lysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis
 
(SDS-PAGE) and analyzed by western blot 
as previously described (Laemmli 1970). Nitrocellulose membranes were 
probed with antibodies to phospho-Ser
473
Akt/PKB, phospho-Thr
202
/Tyr
204
  
ERK and actin (CELL-SIGNALING Techology). Immunoreactive bands were 
detected by enhanced chemiluminescence according to the manufacturer‘s 
instructions (GE Healthcare, NJ). 
 
 
3.6 Bioplex Cytokine and Growth Factor Assay 
 
Supernatants were collected after 12 h of plating the different cells. 
Concentrations of IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL- 
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12 (p40), IL-12(p70), IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN- , KC, 
MCP-1, MIP-1α, MIP-1β,  RANTES, TNF- , PDGF, VEGF and IGF1 were 
determined using the Bioplex multiplex Mouse Cytokine and Growth factor 
assay kits (Bio-Rad, Hercules, CA) according to the manufacturer‘s protocol. 
Briefly, 50 l of the culture supernatant or cytokine standard was plated in a 96 
well filter plate coated with a multiplex of beads coupled to antibodies against 
the above mentioned cytokines and incubated for 30 min on a platform shaker 
at 300 rpm at RT. After a series of washes to remove the unbound proteins, a 
mixture of biotinylated detection antibodies, each specific for a different 
epitope was added to the reaction resulting in the formation of antibodies 
assimilated around the target proteins. Streptavidin-phycoerythrin 
(streptavidin-PE) was then added to bind to the biotinylated detection 
antibodies on the bead surface. The data from the reaction were then collected 
and analyzed by using the Bio-Plex suspension array system (or Luminex 100 
system) from Bio-Rad Laboratories (Hercules, CA). 
 
 
3.7 Real-time PCR 
 
Total RNA was isolated from 3T3 L1 pre-adipocytes and adipocytes by 
using the Rneasy Kit (Qiagen Sciences) according to the manufacturer‘s 
instruction. For real-time RT-PCR analysis, 1 μg cell RNA was reverse 
transcribed using SuperScript II Reverse Transcriptase (Invitrogen). PCR were 
analyzed using SYBR Green mix (Invitrogen). Reactions were performed using 
Platinum SYBR Green Quantitative PCR Super-UDG using an iCycler IQ 
multicolour Real-Time PCR Detection System (Biorad Hercules, CA). All 
reactions were performed in triplicate and GAPDH was used as an internal 
standards. Primer sequences used were as follows: IGF1 forward primer 5‘- 
TGG ATG CTC TTC AGT TCG TG -3‘, reverse primer 5‘- TTT TGT AGG 
CTT CAG TGG GG -3‘. 
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3. RESULTS AND DISCUSSION 
 
4.1 Evaluation of the effect of the adipocyte conditioned media on breast 
cancer cell growth. 
 
The adipocyte represents one of the most abundant cell types 
surrounding cancer cells and could influence several aspects of tumorigenesis, 
from promoting local invasion to angiogenesis and metastasis to distant sites 
that are fat enriched (Iyengar et al. 2003). However, it is not known how 
adipocytes influence breast tumor cell behaviour or whether any of the 
paracrine factors secreted by adipocytes cause changes in the malignant 
phenotype. 
 
 
Fig. 6: Effect of adipocyte conditioned media on MCF7 cell growth. Undifferentiated 3T3-L1 cells or mature 3T3-
L1 adipocytes have been incubated with serum-free DMEM for 8h. Media have been collected (respectively Fibro CM, 
yellow bar, and Adipo CM, green bar) and added to serum-starved MCF-7 breast cancer cells for 6, 12 and 24 h, as 
indicated. As a control, MCF7 cells have also been incubated with DMEM without serum supplementation (DMEM-
BSA, blue bar) or with 10% fetal bovine serum (DMEM 10%FBS, purple bar). Then, cells have been counted and the 
results reported as fold-increase over basal (cell count in DMEM-BSA). Asterisks denote statistically significant values 
(* p<0.05; ** p<0.01; *** p<0.005). 
 
I studied whether adipocyte-derived factors may affect the growth of 
breast cancer cells. For these studies 3T3-L1 cells, an established model of 
differentiating adipocytes, and MCF-7, a well studied breast cancer cell line 
were chosen. In conditioned media (‗CM‘) assay, 3T3-L1 fibroblasts and 
adipocytes were allowed to secrete factors into serum-free medium (‗DMEM-
BSA‘). After 8h, medium was collected and applied to MCF-7 cells for 6, 12 
and 24h (respectively ‗Fibro CM‘ and ‗Adipo CM‘). As control, MCF-7 cells 
were incubated for the same time in the presence of DMEM-BSA (negative 
control), or in presence of DMEM 10% FBS (standard growth conditions for 
MCF-7 cells), as positive control. MCF-7 cells were subsequently trypsinized 
and counted. As shown in fig. 6 conditioned media obtained from 3T3-L1 cells 
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induced growth of MCF-7 cells, in a time-dependent manner. Breast cancer 
cell growth reached levels similar to those observed for cells incubated with 
DMEM 10%FBS. Interestingly, however, conditioned media from fully 
differentiated adipocytes (green bar) are significantly more effective than 
conditioned media from pre-adipocytes (yellow bar) in inducing MCF-7 
growth. 
In order to address whether these changes are due to reduced cell death 
or to increased proliferation, I performed cytofluorimetric determinations of 
cell cycle phases.   
To this aim MCF-7 cells were exposed to serum-free media for 16h and 
then incubated with ‗Fibro CM‘ or ‗Adipo CM‘ for 12h. The induction of 
apoptosis/necrosis was analyzed by a spectrum of flow cytometric assays. The 
phases of the cell cycle and the occurrence of a sub-G1 peak were determined 
with propidium iodide staining. 
The MCF-7 cells exposed to DMEM 10%FBS displayed a normal 
distribution among the phases of cell cycle while, serum-free media treatment 
(DMEM-BSA) induced significant accumulation of cells in the G0/G1 phase 
that is indicative of cell death. Interestingly, the incubation with conditioned 
media protected cells from serum starvation-induced cell death and ‗Adipo-
CM‘ was more effective than ‗Fibro-CM‘ (Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Effect of conditioned media on MCF-7 apoptosis/necrosis. MCF-7 cells were starved for 16h and incubated 
with conditioned media from fibroblast (Fibro CM) or adipocyte (Adipo CM) for 12h. MCF-7 cells were treated with 
propidium iodide staining and ratio of sub-G1 phase was analyzed by flow cytometric assays (* p<0.05). 
 
It has been clearly demonstrated that several growth factors, including 
IGF1, promote cell proliferation and protect cells from apoptosis activating 
MAPK and PI3K pathways (Robbins and Cotran 2004). 
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I therefore hypothesized that Adipo CM could contain growth factors 
able to activate these transduction pathways. AKT and ERK are the main 
proteins downstream PI3K and MAPK signaling respectively. AKT is activated 
by phosphorylation at  Ser
473
,while ERK is activated when is phosphorylated 
on Thr
202
/Tyr
204
. 
I evaluated AKT and ERK phosphorylation in MCF-7 cells upon Adipo 
CM treatment using phospho-specific antibodies. 
MCF-7 cells have been treated with Adipo CM for 10 min and 12h or 
with 100 ng/ml IGF1 as positive control. As shown in fig. 8, Adipo CM  
rapidly induced the phosphorylation of ERK on Thr
202
/Tyr
204
 and of AKT on 
Ser
473
 after 10 min of treatment. However, after 12h ERK phosphorylation was 
reduced while AKT phosphorylation was preserved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Effect of Adipo CM on PI3K and MAPK signaling. MCF-7 cells were starved for 16 h and stimulated with  
Adipocyte conditioned media (Adipo CM) or with 100ng/ml IGF-1 for the indicated times. Then the cells were 
solubilysed as described in Materials and Methods. Cell lysates were blotted with specific anti-phospho-Serine473–
Akt/PKB antibody (pAkt) and anti-phospho-Threonine202/Tyrosine204-ERK antibody (pERK).and then reblotted with 
anti-Akt/PKB and ERK antibodies. To ensure the equal protein transfer, membranes were blotted with actin antibodies  
 
 
Next, I have investigated whether human adipocytes were as effective 
as murine cell lines. To this end I have isolated adipocytes by surgical 
specimens. I have incubated whole adipose tissue and isolated adipocytes in a 
specific culture media and, after 4h, I have collected the conditioned media and 
placed them onto MCF-7 for 8 and 24h. MCF-7 cells were subsequently 
trypsinized and counted. As shown in fig. 9, conditioned media from both 
whole adipose tissue and isolated adipocytes induced growth of MCF-7 cells. 
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Fig. 9: Effect of humane adipocyte conditioned media on MCF-7 cell growth. 300mg of adipose tissue or of 
isolated adipocytes have been incubated with basal medium for 4h. Media have been collected  and added to serum-
starved MCF-7 breast cancer cells for 8 and 24 h, as indicated. As a control, MCF-7 cells have also been incubated 
with basal medium. Then, cells have been counted and the results reported as fold-increase over basal (cell count in 
basal medium). 
 
 
4.2 Evaluation of the effect of insulin and glucose on adipocyte ability to 
promote breast cancer cell growth. 
 
Metabolic disorders are strongly associated with obesity and an 
increased risk for several types of cancer. Therefore, I examined whether 
perturbations of the metabolic environment may affect the growth-promoting 
properties of adipocytes. To this end 3T3-L1 cells were incubated in the 
presence of low concentrations of glucose, prior to measure the ability of their 
conditioned media to induce growth of cancer cells. In detail, 3T3-L1 
adipocytes were cultured either in regular medium (containing 25,5 mM 
glucose) or in low-glucose medium (5,5 mM glucose) for 24h, than the 
medium was changed and the cells were allowed to secrete factors into serum-
free medium (‗DMEM-BSA‘). After 8h, medium was collected and applied to 
MCF-7 cells for 6, 12 and 24h. As control, MCF-7 cells were incubated for the 
same time in the presence of DMEM-BSA (negative control), or in presence of 
DMEM 10% FBS, as positive control. MCF-7 cells were subsequently 
trypsinized and counted. As shown in fig. 10, the treatment of adipocytes with 
low glucose (fig. 10a, orange bar) impairs their ability to induce growth of 
MCF-7 cells. 
Similarly, when 3T3-L1 adipocytes were treated with insulin (fig. 10b), 
in order to increase glucose utilization, their conditioned medium failed to 
increase MCF-7 cell growth. 
All together, these data suggest that glucose metabolism in adipocytes 
may affect their ability to promote cancer cell growth.  
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a) 
 
b) 
 
Fig. 10: Effect of glucose or insulin on adipocyte growth-promoting action. 3T3-L1 adipocytes have been pre-
incubated with regular DMEM containing 25 mM glucose or with DMEM containing 5 mM glucose (Low Glucose 
medium) for 24 h (a) or with 100 nM insulin for 16h (b). Then, they have been further incubated with regular serum-
free DMEM for 8 h. Media have been collected and added to serum-starved MCF-7 breast cancer cells for 6, 12 and 
24h, as indicated. As a control, MCF-7 cells have also been incubated with DMEM without serum supplementation 
(DMEM-BSA) or with 10% fetal bovine serum (DMEM 10%FBS). Then, cells have been counted and the results 
reported as fold-increase over basal (cell count in DMEM-BSA). Asterisks denote statistically significant values (* 
p<0.05). 
 
 
4.3 Identification of the adipocyte factors controlling breast cancer cell 
phenotypes.  
 
White adipose tissue expresses and secretes a variety of adipokines, 
proinflammatory cytokines and growth factors (Iyengar et al. 2003; Ahima and 
Flier 2000). 
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In order to identify the factors released from the adipocytes which may 
be contributing to the malignant phenotype of breast cancer cells I used 
ELISA/multiplex analysis. In particular, I analyzed the conditioned media for 
the content of growth factors and cytokines produced by pre-adipoctytes or 
adipocytes, in presence or absence of low glucose medium or insulin. 
Conditioned media were collected and tested for 23 cytokines and 3 growth 
factors by using the Bioplex multiplex cytokine assay kit and the Bioplex 
multiplex growth factor assay kit. In tab. 2 are shown all the cytokines and 
growth factors analyzed and their changes in both conditioned media. As 
shown, in Adipo CM there is an increase of IL-12 (p40), INF- MIP-1 , 
RANTES and IGF1 and a reduction of KC, MCP-1 and MIP-1 compared to 
Fibro CM. The levels of IL-1  and IL-3 are similar in both media. Other 
cytokines were not detectable. 
 
a) 
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b) 
 
 
Tab. 2: Screening of cytokines and growth factors present in Adipo CM. Supernatants from adipocytes (Adipo 
CM), fibroblast (Fibro CM), adipocyte pretreated with low glucose medium (Adipo-LG CM) or with insulin 
(Adipo+INS CM) were collected from 8h and tested for 23 cytokines and 4 growth factors by Bioplex multiplex assay. 
 
 
It should be noted that IL-12 is secreted only by adipocyte, while 
RANTES, MIP-1a and IGF1 are secreted by both preadipocytes and 
adipocytes, but their concentration is higher in Adipo CM than in Fibro CM.  
Incubation in Low glucose medium or with insulin led to changes in 
adipocyte-released factors. In Adipo-LG CM and Adipo +INS CM there was a 
decrease of RANTES and IGF1  and an increase of KC compared to Adipo 
CM. The levels of MCP-1 were similar in Adipo CM and Adipo-LG CM, but 
reduced in Adipo +INS CM.  
In conclusion, in Adipo CM there was a reduction of KC and an 
increase of RANTES and IGF1 compared to Fibro CM. Low glucose or insulin 
treatment of adipocytes rescued these differences. 
Except for the IGF1, the role of these cytokines in cancer is largely 
unknown, so it remains to elucidate how they may promote breast cancer cell 
survival or growth. 
 
 
4.4 IGF1 expression and inhibition. 
 
In order to investigate the molecular basis of the differential IGF1 
secretion, I have measured the expression levels of IGF1 by real-time RT-PCR 
in pre-adipocytes and adipocytes cultured or not in presence of low glucose 
medium or insulin 
As shown in fig. 11, in adipocytes the IGF1 mRNA levels were 3-fold 
higher than those detected in pre-adipocytes. 
Incubation with either low glucose medium or insulin reduced IGF1 
mRNA levels in adipocytes (Fig. 11). 
Then I have tested the possibility that the growth effect of adipocyte 
conditioned media could be reverted by inhibiting IGF-1 pathway. Therefore, 
3T3-L1 adipocytes conditioned media were collected and applied to MCF-7 
cells for 12h in the presence of 10 µM AG1024, a specific IGF-1R tyrosine 
kinase inhibitor.  
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Fig. 11:IGF1 expression. The abundance of mRNA for IGF1 was determined by real-time PCR analysis of total RNA 
isolated from 3T3 L1, adipocyte 3T3L1 (Adipo 3T3L1), adipocyte 3T3L1preincubated 24h in low glucose medium 
(Adipo 3T3L1 LG) and adipocyte 3T3L1 pretreated with 100 nM insulin for 16h (Adipo 3T3L1+INS). Bars represent 
the mRNA levels in these cells and are relative to those in adipocyte 3T3 L1 cells.  
 
Fig. 12: Effect of AG1024 on adipocyte and pre-adipocyte growth-promoting action. MCF-7 cells have been 
treated with 10 µM AG1024 for 15min, then, they have been further incubated with Adipo CM or Fibro CM for 12h. 
As a control, MCF7 cells have also been incubated with DMEM without serum supplementation (DMEM-BSA) or 
with 10% fetal bovine serum (DMEM 10%FBS). Then, cells have been counted and the results reported as fold-
increase over basal (cell count in DMEM-BSA). 
 
As shown in fig. 12, the treatment of MCF-7 cells with IGF-1R 
inhibitor AG1024 (fig. 12, respectively red and dark green bars) impaired the 
ability of Adipo CM and Fibro CM to induce cell growth, suggesting the 
crucial role of adipocyte produced IGF1 in promoting cancer cell growth. 
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5. CONCLUSIONS 
 
 
Adipocyte conditioned media stimulate MCF-7 cell proliferation; interestingly, 
conditioned media from fully differentiated adipocytes are significantly more 
effective than conditioned media from pre-adipocytes in inducing MCF-7 
growth. This effect is obtained also with human adipocytes. 
Adipocyte conditioned media reduce MCF-7 apoptosis and activate 
ERK1/2 and AKT resulting in protection from apoptosis.  
The incubation of adipo 3T3L1 cells with low glucose medium or with 
insulin impair their ability to induce MCF7 growth suggesting that glucose 
metabolism in adipo 3T3L1 cells is crucial.  
Finally, cytokines/growth factors screening revealed that KC, RANTES 
and IGF1 could be good candidates in mediating pro-tumorigenic effect of 
adipocyte conditioned media. In particular, adipocyte conditioned media 
proliferative effect is reverted by inhibiting IGF-1 pathway suggesting the 
crucial role of adipocyte produced IGF1 in promoting cancer cell growth. 
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ABSTRACT
The endocannabinoid system regulates food intake, energy,
and glucose metabolism at both central and peripheral levels.
We have investigated the mechanism by which it may control
glucose uptake in skeletal muscle cells. Detectable levels of the
cannabinoid receptor type 1 (CB1) were revealed in L6 cells.
Exposure of differentiated L6 myotubes to the CB1 antagonist
rimonabant (SR141716) selectively increased 2-deoxyglucose
uptake (2-DG) in a time- and dose-dependent manner. A similar
effect was induced by genetic silencing of CB1 by small inter-
fering RNA. Protein expression profiling revealed that both the
regulatory p85 and the catalytic p110 subunits of the phosphati-
dylinositol-3-kinase (PI3K) were increased by SR141716. No sig-
nificant change in the cellular content of other known molecules
regulating PI3K was observed. However, phosphoinositide-
dependent kinase-1, Akt/protein kinase B, and protein kinase
C activities were rapidly induced after SR141716 treatment
of L6 cells in a PI3K-dependent manner. The stimulatory effect
of SR141716 on PI3K expression and activity was largely
prevented by N-[2-(4-bromocinnamylamino)ethyl]-5-isoquino-
line (H-89), an inhibitor of the cAMP-dependent protein kinase.
Moreover, SR141716-stimulated 2-DG uptake was blunted
by the coincubation either with H-89 or with the PI3K inhib-
itor 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hy-
drochloride (LY294002), both in L6 cells and in mouse pri-
mary myocytes. Thus, modulation of CB1 regulates glucose
uptake at the level of the PI3K signaling system in skeletal
muscle cells. Interfering with CB1 signaling may therefore
ameliorate glucoregulatory functions in peripheral tissues.
Type 2 diabetes (T2D) is a genetically determined disorder,
affecting more than 150 million people worldwide. T2D is char-
acterized by several metabolic defects, among which -cell se-
cretory dysfunction and peripheral insulin resistance are con-
sidered as hallmarks of the disease in humans (Kahn, 2003).
Common forms of T2D arise because of the progressive failure
of endocrine pancreas to adequately cope with the increased
insulin demand in insulin-resistant states (Lazar, 2005). In
particular, obesity is believed to play a central role as a caus-
ative factor of insulin resistance (Lazar, 2005). Moreover, ge-
netic and functional abnormalities found in obese individuals
show a certain degree of overlap with those detected in patients
with T2D, suggesting that common molecular events may con-
tribute to the onset and/or the progression of both disorders.
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These defects may affect feeding behavior, as well as energy
expenditure and nutrient metabolism.
The endocannabinoid system, for instance, is an important
regulator for all of those functions (Boyd, 2006; Pagotto et
al., 2006). Elevated levels of the endogenous cannabinoids
(anandamide and 2-arachidonoyl-glycerol) have been found
in obese individuals (Engeli et al., 2005; Osei-Hyiaman et al.,
2005, 2006) and correlate with intra-abdominal adiposity
(Cote et al., 2007). Both exogenous cannabinoids and endo-
cannabinoids increase food intake and promote weight gain
by activating the specific CB1 receptor (Jamshidi and Taylor,
2001; Williams and Kirkham, 2002; Cota et al., 2003a). Mice
carrying the ablation of the CB1 gene are lean and resistant
to diet-induced obesity (Ravinet Trillou et al., 2004). It has
been shown recently that rimonabant (SR141716), a CB1-
receptor inverse agonist (Bouaboula et al., 1997), produces a
marked and sustained decrease in body weight, which is
associated with favorable modifications in serum biochemical
and lipid profiles (Poirier et al., 2005; Pi-Sunyer et al., 2006).
Long-term blockade of the CB1 receptor is also accompa-
nied by reduced blood pressure and fasting glucose and in-
sulin levels (Ravinet Trillou et al., 2003; Poirier et al., 2005;
Van Gaal et al., 2005). Nevertheless, whether these addi-
tional beneficial effects are merely the consequence of weight
loss or are the result of peripheral actions of the CB1-tar-
geted molecules is still unknown. It has been shown that CB1
receptors are expressed in several mammalian tissues rele-
vant to insulin action (Engeli et al., 2005; Juan-Pico et al.,
2006). For instance, pancreatic islets express functional can-
nabinoid receptors, which may regulate Ca2 signals and
insulin secretion (Juan-Pico et al., 2006). In the liver, the
activation of CB1 increases de novo synthesis of fatty acids by
activating the transcription factor sterol regulatory element
binding protein 1c (Osei-Hyiaman et al., 2005). In addition,
modulation of CB-1 activity in isolated mouse adipocytes
increases the activity of the lipogenic enzyme lipoprotein
lipase (Cota et al., 2003b) and adiponectin expression (Ben-
said et al., 2003). Very little information is available, how-
ever, concerning cannabinoid receptor function in the skele-
tal muscle. Recently, CB1 expression has been detected in
soleus muscle (Pagotto et al., 2006), and SR141716 has been
shown to affect glucose uptake in the isolated soleus of ge-
netically obese mice (Liu et al., 2005) and the expression of
genes involved in oxidative metabolism (Cavuoto et al.,
2007). However, the molecular mechanisms of CB1 action in
skeletal muscle cells remain largely undefined.
We now show that in a skeletal muscle cultured cell
model, the L6 cells, pharmacological regulation of the en-
docannabinoid system controls glucose uptake at the level
of the phosphatidylinositol-3-kinase (PI3K). In particular,
the CB1 inverse agonist SR141716 selectively increases
PI3K expression and activity in a protein kinase A (PKA)-
dependent manner. This, in turn, leads to changes of the
PI3K downstream signaling and a consequent regulation
of glucose uptake in the skeletal muscle cells.
Materials and Methods
General. Media, sera, and antibiotics for cell cultures were from
Invitrogen Ltd. (Paisley, United Kingdom). Phospho-Ser241 PDK1,
phospho-Ser473 PKB, phospho-serine, and phospho-Thr202/Tyr204
extracellular signal-regulated kinase antibodies were purchased from
Cell Signaling Technology (Danvers, MA). Actin antibody was from
Sigma (St. Louis, MO). Antibodies directed against CB1, GLUT1,
GLUT4, extracellular signal-regulated kinases, phospho-Thr410
PKC, PKC, p110, PTEN, PKB, CREB, and phospho-Ser133 CREB
were from Santa Cruz Biotechnology (Santa Cruz, CA). PDK1, IRS-1,
IRS-2, and p85 antibodies were from Upstate Cell Signaling Tech-
nology (Lake Placid, NY). Electrophoresis and Western blot reagents
were from Bio-Rad (Richmond, VA). 2-Deoxy-[14C]-glucose and en-
hanced chemiluminescence reagents were from GE Healthcare
(Chalfont St. Giles, Buckinghamshire, UK). Other reagents were
from Sigma.
Cell Culture. The L6 skeletal muscle cells were plated (6  103
cells/cm2) and grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) fetal bovine serum and 2 mM
glutamine. Cultures were maintained at 37°C in a humidified atmo-
sphere containing 5% (v/v) CO2. L6 differentiation was achieved as
described previously (Caruso et al., 1997).
Mouse Primary Fibroskeletal Muscle Cell Culture. Skeletal
muscle biopsies were obtained after C57 BL6 strain (n  9) mice
were sacrificed by pentobarbitone overdose, as described previously
(Kra¨mer et al., 2007). The biopsies were collected in cold phosphate-
buffered saline supplemented with 1% PeSt (100 U/ml penicillin, 100
g/ml streptomycin), dissected, finely minced, and transferred to a
digestion solution (0.015 g Collagenase IV, 8% 10 trypsin, 0.015 g
of bovine serum albumin, 1% PeSt, in DMEM supplemented with
10% fetal calf serum, 10,000 U/ml penicillin, 10 mg/ml streptomycin,
and 2% L-glutamine) and incubated with gentle agitation at 37°C for
15 to 20 min. Thereafter, undigested tissue was allowed to settle, and
the supernatant was collected and mixed with DMEM supplemented
with 20% fetal calf serum and 1% PeSt. The remaining tissue was
digested for a further 15 to 20 min at 37°C with fresh digestion
solution. The resultant supernatant was then pooled with the previ-
ous cells and centrifuged for 10 min at 350g. The cell pellet was
resuspended in DMEM supplemented with 20% fetal calf serum and
1% PeSt and was then seeded and grown in culture flask. After this,
medium was again changed to DMEM supplemented with 10% fetal
calf serum and 1% PeSt. Before any experiment, cells were incubated
in serum-free media for 16 h and stimulated with insulin or with
SR141716 as indicated.
Cell Treatment. For all of the experiments, L6 cells and myo-
cytes were incubated in serum-free media supplemented with 0.25%
bovine serum albumin. Unless specified, different concentrations of
SR141716 (0.05, 0.1, 0.3, 1, and 10 M) were simultaneously added
to the media, as described in the figure legend. Likewise, 0.1 M
SR144528 and 0.3 M iodoresinatoxin (IRTX) were added to the
serum-free media for the indicated time. For PI3K inhibition studies,
cells were pretreated with 10 M LY294002 for 30 min followed by
further incubation with LY294002 and 0.1 M SR141716 for addi-
tional 24 h. For early times, the cells were serum-starved for 16 h
and then pretreated with 10 M LY294002 for 30 min, followed by
further incubation with LY294002 and 0.1 M SR141716 for an
additional 30 min. For PKA inhibition studies, cells were pretreated
with 15 M H-89 for 30 min followed by combined treatment with
H-89 and 0.1 M SR141716 for an additional 30 min or 24 h as
indicated. To study the SR141716 effect on protein synthesis, the
cells were incubated with 40 g/ml cycloheximide in presence of 0.1
M SR141716 for 24 h.
Transient Transfection. For knocking down CB1 expression, a
21-nucleotide small interfering RNA duplex (Dharmacon Research,
Lafayette, CO) was used, designed for specific silencing of CB1
(siRNA-CB1), covering the sequence sense 5-CCCAAGUGAC-
GAAAAACAUU-dTdT-3. The cells were transfected using FuGENE
(Roche, Indianapolis, IN) and 100 nM siRNA for each transfection, in
accordance with the manufacturer’s instruction. An equal concentra-
tion of Silencer Negative Control-1 siRNA (Ambion, Austin, TX) was
used as negative control. Transfected L6 cells were serum-starved
and incubated with 0.1 M SR141716 and after 16 h assayed for
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2-deoxy-D-glucose uptake. Specific silencing of CB1 gene was con-
firmed by RT-PCR and Western blot analysis for CB1 receptor.
Real-Time PCR. Total RNA was isolated from 3T3 L1 preadipo-
cytes and L6 cells by using the RNeasy Kit (QIAGEN Sciences,
Valencia, CA) according to the manufacturer’s instruction. For real-
time RT-PCR analysis, 1 g of cell RNA was reverse-transcribed
using SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad,
CA). PCR was analyzed using SYBR Green mix (Invitrogen). Reac-
tions were performed using Platinum SYBR Green Quantitative
PCR SuperUDG using an iCycler IQ multicolor Real-Time PCR
Detection System (Bio-Rad, Hercules, CA). All reactions were per-
formed in triplicate, and -actin was used as an internal standard.
Primer sequences used were as follows: CB1R sense, 5-CTA CTG
GTG CTG TGT GTC ATC-3; antisense, 5-GCT GTC TTT ACG GTG
GAA TAC-3; and -actin: forward, 5-GCGTGACATCAAAGA-
GAAG-3; reverse, 5-ACTGTGTTGGCATAGAGG-3.
Immunoblot Analysis and Immunoprecipitation Procedure.
Cells were solubilized for 20 min at 4°C with lysis buffer containing 50
mM HEPES, 150 mM NaCl, 10 mM EDTA, 10 mM Na4P2O7, 2 mM
sodium orthovanadate, 50 mM NaF, 1 mM phenylmethylsulfonyl fluo-
ride, 10g/ml aprotinin, 10g/ml leupeptin, pH 7.4, and 1% (v/v) Triton
X-100. The lysates were clarified by centrifugation at 12,000g for 20min
at 4°C. Proteins were separated by SDS-polyacrylamide gel electro-
phoresis and blotted on Immobilon-P membranes (Millipore, Billerica,
MA). Membranes were blocked for 1 h in Tris-buffered saline (10 mM
Tris-HCl, pH 7.4, and 140 mMNaCl) containing 4% (w/v) bovine serum
albumin and then incubated with the indicated antibodies. Detection of
blotted proteins was performed by enhanced chemiluminescence ac-
cording to the manufacturer’s instruction. Immunoprecipitation exper-
iments were performed as described previously (Formisano et al., 1998).
Densitometric analysis was performed using a Scion Image Analyzer.
All of the data were expressed as mean  S.D. Significance was as-
sessed by Student’s t test for comparison between two means. Data
were analyzed with Statview software (Abacus Concepts, Piscataway,
NJ) by one-factor analysis of variance. P values of less than 0.05 were
considered statistically significant.
2-Deoxy-D-glucose Uptake. The measurement of 2-deoxy-D-
[14C]glucose uptake was taken as a measure of glucose uptake by
muscle cells, as described previously (Klip et al., 1982). Cells were
incubated in serum-free Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 0.2% (w/v) bovine serum albumin for 18 h in the
presence or absence of SR141716 at different concentrations. Cells were
incubated in glucose-free 20 mM HEPES, pH 7.4, 140 mM NaCl, 2.5
mM MgSO4, 5 mM KCl, 1 mM CaCl2 (HEPES buffer) and exposed or
not to 100 nM insulin for 30 min. Glucose uptake was measured by
incubating cells with 0.15 mM 2-deoxy-D-[14C]glucose (0.5 Ci/assay)
for 15 min in HEPES buffer. The reaction was terminated by the
addition of 10Mcytochalasin B, and the cells werewashed three times
with ice-cold isotonic saline solution before lysis in 1 M NaOH. Incor-
porated radioactivity was measured in a liquid scintillation counter.
Measurement of Intracellular cAMP. Cells were plated in
12-well plates at a density of 5  105 cells/well. Cells were treated
with 1 M forskolin for 30 min and with 0.1 M SR141716 for 24 h.
After treatment, cells were washed twice with cold phosphate-buff-
ered saline, and intracellular cAMP was extracted by the addition of
500 l of 0.1 N HCl with 0.1% Triton, followed by three cycles of
freezing and thawing. cAMP concentration was measured by radio-
immunoassay (PerkinElmer Life and Analytical Sciences, Waltham,
MA) (Nikodemova et al., 2003).
Results
Effect of CB1 Modulation on Glucose Uptake. To in-
vestigate whether the endocannabinoid system may operate
in a skeletal muscle cell model, we measured the expression
levels of the CB1 receptor by real-time RT-PCR and immu-
noblot experiments in the L6 myotubes (Fig. 1). As control,
we used 3T3 L1 cells, in which CB1 expression has already
been described previously (Yan et al., 2007). In L6 myotubes,
the CB1 mRNA (Fig. 1A) and protein (Fig. 1, B and C) were
expressed at levels similar to those detected in 3T3 L1 cells.
Next, 2-deoxy-glucose (2-DG) uptake was measured in the
myotubes in the absence or presence of increasing concentra-
tions of the CB1 receptor inverse agonist SR141716 (Fig. 2A).
At variance, preincubation of L6 myotubes with 0.1 and 0.3
M SR141716, respectively, led to 50 and 45% increases of
2-DG uptake (p  0.001), only slightly lower than that ob-
served upon acute insulin stimulation (100 nM for 30 min).
No effect was observed with 0.05 M SR141716 (Fig. 2A).
Increasing SR141716 concentrations to 1 and 10 M led to a
progressive reduction of 2-DG uptake, however, consistent
with a partial agonist effect. In addition, no significant effect
was achieved after treatment of L6 cells with 0.1 M
SR144528 (a selective CB2 receptor antagonist) and 0.3 M
IRTX, a potent transient receptor potential vanilloid 1 recep-
tor antagonist (Fig. 2A). Time course analysis revealed that
the effect of 0.1 M SR141716 was rapidly induced upon
30-min treatment and persisted up to 16 h (Fig. 2B) and
longer (up to 72 h, data not shown).
Fig. 1. CB1 expression in myoblasts and myotubes. A, the abundance of
mRNA for CB1 was determined by real-time PCR analysis of total RNA
isolated from 3T3 L1 cells and L6 myotubes. The results have been
analyzed as described under Materials and Methods. Bars represent the
mRNA levels in L6 myotubes and are relative to those in 3T3 L1 cells.
Data are expressed as means S.D. of triplicate reactions for total RNAs
from each cell type in five independent experiments. B, 3T3 L1 and L6
were solubilized, and cell lysates were separated on SDS-PAGE and
immunoblotted with CB1 antibodies. The autoradiograph shown is rep-
resentative of five independent experiments in duplicate. C, filters ob-
tained in B have been analyzed by laser densitometry as described under
Materials and Methods.
1680 Esposito et al.
Protein Expression Profile upon CB1Modulation. To
address the mechanism by which CB1 may regulate glucose
uptake in the L6 cells, protein lysates were obtained after-
treatment with 0.1 M SR141716 for 16 h. Protein expres-
sion profiling was achieved by immunoblot with specific an-
tibodies (Table 1). The intracellular content of the regulatory
(p85) and the catalytic (p110) subunits of class I PI3K was
increased by 2.0- and 1.7-fold, respectively, upon SR141716
exposure (Table 1 and Fig. 3). No significant change, instead,
was detected for the insulin receptor, IRS-1 and -2, phospho-
inositide-dependent-kinase 1, and protein kinase C, as well
as for the lipid phosphatase PTEN and glucose transporters
GLUT-1 and -4 (Table 1). The expression levels of protein
kinase B/Akt1 were also increased by SR141716, although
differences did not reach statistically significant values
(Table 1). We then evaluated the timing of PI3K regulation
by CB1. The treatment of L6 cells with SR141716 for 5 h
led to a slight increase of p85 expression, which increased
up to 24 h and remained stable for up to 72 h (Fig. 3C). No
detectable change was observed upon 30-min exposure to
SR141716. Very similar results were obtained with p110
(data not shown).
To assess whether CB1-mediated regulation of p85 expres-
Fig. 2. 2-DG uptake upon SR141716 incubation. A, L6 myotubes were
incubated in serum-free media for 16 h before exposure to 100 nM insulin
for 30 min as indicated. On the other hand, increasing concentrations
(0.05, 0.1, 0.3, 1, and 10 M) of SR141716, or 0.1 M SR144528 or 0.3 M
IRTX was simultaneously added to serum-free media for 16 h (in the
absence of insulin). Then the cells were assayed for 2-DG uptake as
described under Materials and Methods. Bars represent mean  S.D. of
three different experiments in triplicate. Asterisks indicate statistically
significant differences versus untreated cells (, p  0.001). B, the cells
were treated with 0.1 M SR141716 for different times (as indicated).
2-DG uptake assay was performed as described under Materials and
Methods. Bars represent mean  S.D. of three different experiments in
triplicate. Asterisks indicate statistically significant differences versus
untreated cells (, p  0.001).
TABLE 1
Effect of SR141716 on proteins involved in glucose uptake
The cells were incubated or not with 0.1 M SR141716 for 16 h. Filters were
immunoblotted with specific antibodies as indicated and analyzed by laser densi-
tometry, as described under Materials and Methods. The values have been normal-
ized to the actin levels and represent means  S.D. of three independent experi-
ments in duplicate.
Protein SR141716
% of control
Insulin receptor 108  8.4
IRS1 107  7.0
IRS2 100  5.4
p85 196  8.8***
p110 168  9.3*
PDK1 99  9.2
PKC 112  5.6
Akt/PKB 123  16.9
PTEN 107  10.2
GLUT1 100  11.2
GLUT4 108  7.8
* P  0.05; *** P  0.001 (statistically significant difference of the samples
obtained from treated versus untreated cells).
Fig. 3. p85 and p110 regulation by SR141716. A, L6 myotubes were
serum-starved and incubated with 0.1 M SR141716 for 16 h, as de-
scribed in the legend to Fig. 2 and under Materials and Methods. Cell
lysates were separated on SDS-PAGE and analyzed by p85, p110, and
-actin immunoblot. The autoradiographs shown are representative of
five independent experiments. B, filters obtained in A were analyzed by
laser densitometry as described under Materials and Methods. Asterisks
indicate statistically significant differences (, p  0.001). C, cells were
treated with 0.1 M SR141716 for different times as indicated. Cell
lysates were then analyzed by p85 and -actin immunoblot as indicated.
The autoradiographs shown are representative of five independent ex-
periments. Then, filters obtained in C were analyzed by laser densitom-
etry as described under Materials and Methods. Asterisks indicate sta-
tistically significant differences (, p  0.001; , p  0.01).
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sion occurred at the level of protein synthesis, L6 cells were
treated with 40 g/ml cycloheximide (CHX). At the baseline,
CHX treatment reduced p85 cellular abundance (Fig. 4, A
and B). The treatment with SR141716, however, was still
able to increase p85 immunodetection, indicating that regu-
lation occurred at a post-translational level. Similar results
were obtained with p110 (data not shown). Consistent with
this hypothesis, CHX did not affect SR141716-induced 2-DG
uptake (Fig. 4C).
It has been shown previously that CB1 receptor may reg-
ulate PKA activity (Bidaut-Russell et al., 1990). To investi-
gate whether SR141716 may regulate PKA activity in the L6
cells, we evaluated the phosphorylation of its substrate,
CREB. Immunoblot with specific antibodies revealed that
SR141716 induced the phosphorylation of CREB on Ser133
(Fig. 5, A and B). We have therefore tested whether PKA
inhibition was able to revert the SR141716 effect on p85. To
this end, L6 cells were treated with H-89 (15 M), a PKA
inhibitor, in the absence or presence of SR141716. It is in-
teresting that no increase of p85 cellular abundance was
detected in cells treated with H-89 (Fig. 5, A and B). To
further clarify the hypothesis that SR141716 may regulate
PKA activity, we measured intracellular cAMP levels. Incu-
bation of L6 myotubes with 0.1 M SR141716 for 24 h led to
a significant 5-fold increase of intracellular cAMP production
(p  0.001), approximately 50% lower than that observed
upon short-term stimulation (30 min) with 1 M forskolin, a
well known adenylyl cyclase stimulator (Fig. 5C). Moreover,
we have investigated whether SR141716 stimulates p85
phosphorylation via PKA. To this aim, L6 cells were pre-
treated with H-89 for 30 min and stimulated with SR141716
for additional 30 min. SR141716 treatment increased p85
Fig. 4. Effect of CHX on p85 and 2-deoxyglucose uptake. A, cells were
serum-starved and incubated with 40 g/ml cycloheximide in the absence
or in the presence of SR141716 for 24 h, as described in the legend to Fig.
1 and under Materials and Methods. Cell lysates were then analyzed by
immunoblot with p85 and -actin antibodies. The autoradiographs shown
are representative of five independent experiments. B, filters obtained in
A were analyzed by laser densitometry as described underMaterials and
Methods. Asterisks indicate statistically significant differences (, p 
0.001). C, cells were treated as described above and assayed for 2-DG
uptake as described under Materials and Methods. Bars represent
mean  S.D. of three different experiments in triplicate. Asterisks indi-
cate statistically significant differences versus untreated cells (, p 
0.001).
Fig. 5. SR141716 regulates p85 levels via PKA. A, cells were pretreated
with 15 M H-89 and incubated with 0.1 M SR141716 for 24 h, as
described in the legend to Fig. 2 and under Materials and Methods. Cell
lysates were then analyzed by immunoblot with p85, CREB, phospho-
CREB, and -actin antibodies. The autoradiographs shown are represen-
tative of five independent experiments. B, filters obtained in A were
analyzed by laser densitometry as described under Materials and Meth-
ods. Asterisks indicate statistically significant differences (, p 
0.001). C, myotubes were exposed to 1 M forskolin for 30 min and to 0.1
M SR141716 for 24 h. Then the cells were assayed for cAMP production.
Bars represent mean  S.D. of three different experiments in triplicate.
Asterisks indicate statistically significant differences versus untreated
cells (, p  0.001).
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serine phosphorylation, and this effect is prevented by H-89
pretreatment (Fig. 6).
Regulation of PI3K Signaling by CB1. Next, we inves-
tigated whether CB1 modulation affects signaling down-
stream PI3K. To this end, L6 cells have been treated with
0.1 M SR141716. Immunodetection of the phosphorylated
forms of PDK1, Akt/PKB, and PKC was taken as functional
marker for PI3K activity (Fig. 7, A and B). Indeed, these
kinases represent downstream targets of PI3K (Hirsch et al.,
2007). Treatment with SR141716 increased the phosphory-
lation of all these proteins. The positive effect of SR141716 on
PDK1, Akt/PKB, and PKC phosphorylation was already
evident upon 30-min treatment and remained stable up to
24 h (Fig. 7, A and B). L6 myotubes were therefore pretreated
with 10 M LY294002, to block PI3K activity, or with 15 M
H-89, to block PKA activity, and stimulated with 0.1 M
SR141716 for 30 min or for 24 h. In both conditions,
SR141716 failed to induce phosphorylation of PDK1, Akt/
PKB, and PKC (Fig. 8, A and B). In addition, the effect of
SR141716 on 2-DG uptake was blunted after LY294002
and H-89 pretreatment (Fig. 9A). Moreover, we investi-
gated the SR141716 effect on 2-DG uptake in primary
myocytes. Treatment with 0.1 M SR141716 for 30 min or
for 24 h stimulated 2-DG uptake (p  0.01) by approxi-
mately 50%, a level similar to that observed upon short-
term insulin stimulation (100 nM for 30 min) (Fig. 9B). In
addition, the effect of SR141716 on 2-DG uptake was re-
verted after LY294002 and H-89 pretreatment (Fig. 9B).
Effect of CB1 Silencing on Glucose Uptake. Finally,
we investigated whether CB1 silencing affects glucose up-
take induced by SR141716. To this end, L6 cells were trans-
fected with 100 nM siRNA-CB1, which specifically inhibited
CB1 expression by approximately 80% (Fig. 10A). In untrans-
fected L6 cells, SR141716 increased 2-DG uptake. It is inter-
esting that the transfection of siRNA increased glucose up-
take but abolished further increases induced by SR141716
(Fig. 10B). Moreover, the transfection of silencer negative
control siRNA did not modify 2-DG uptake induced by
SR141716 treatment (Fig. 10B).
Discussion
The endocannabinoid system (ECS) is a crucial regulator of
several physiological processes, including the control of en-
ergy balance (Osei-Hyiaman et al., 2006; Pagotto et al., 2006;
Bifulco et al., 2007). Studies in genetically engineered mu-
rine models have, indeed, proven that removal of the CB1
receptor produces lean animals, with grossly modified feed-
ing behavior and increased energy consumption (Ravinet
Trillou et al., 2004). More recent evidence in humans has
indicated that pharmacological blockade of CB1 is accompa-
nied by significant reduction of body weight and of plasma
levels of cholesterol and triglycerides (Despres et al., 2005;
Fig. 6. SR141716 increases p85 phosphorylation via PKA. A, L6 myo-
tubes were pretreated with 15 MH-89 for 30 min and incubated with 0.1
M SR141716 for additional 30 min, as described in the legend to Fig. 2
and under Materials and Methods. Cells were then solubilized, precipi-
tated with anti-p85 antibodies, and immunoblotted with anti phospho-
serine antibodies. The autoradiographs shown are representative of three
independent experiments. B, filters obtained in A were analyzed by laser
densitometry as described under Materials and Methods. Asterisks indi-
cate statistically significant differences (, p  0.05).
Fig. 7. Effect of CB1 modulation on PI3K signaling. A, L6 myotubes were
incubated with 0.1 M SR141716 for different times, as described in the
legend to Fig. 2 and under Materials and Methods. Cells were then
solubilized and phosphorylation and expression of PDK1, PKC, and Akt
were analyzed by Western blot with specific antibodies (phospho-PDK1/
PDK1, phospho-PKC/ PKC, phospho-Akt/Akt) as indicated. The auto-
radiographs shown are representative of three independent experiments.
B, filters obtained in A were analyzed by laser densitometry as described
under Materials and Methods. Asterisks indicate statistically significant
differences (, p  0.01).
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Van Gaal et al., 2005). It also seems that ECS targeting
reduces blood glucose levels (Hollander, 2007) and may di-
rectly regulate glucose metabolism in peripheral tissues. We
have investigated the molecular mechanism by which CB1
exerts its modulatory action in the L6 cells, a well character-
ized model of differentiating skeletal muscle cells (Klip et al.,
1982). Exposure of the myotubes to SR141716 significantly
increased glucose uptake. No effect was elicited, instead, by
SR144528 and IRTX, which are antagonists of CB2 and tran-
sient receptor potential vanilloid 1, respectively. Genetic si-
lencing of CB1 by siRNA, instead, elicited similar effects as
SR141716. This is also in agreement with the recent obser-
vation that treatment of leptin-deficient obese mice with CB1
antagonists enhances glucose uptake by skeletal muscle (Liu
et al., 2005). Therefore, Cavuoto et al. (2007) have shown that
CB1 agonists and antagonists modify the expression of genes
regulating skeletal muscle oxidative pathways. Altogether,
these observations indicate that, in addition to its effect in
the central nervous system (Matias et al., 2006), and similar
as in liver cells and adipocytes (Teixeira-Clerc et al., 2006;
Gasperi et al., 2007), ECS may directly modulate nutrient
metabolism in the skeletal muscle.
Elevated levels of endocannabinoids, which have been found
in obese animal models (Di Marzo et al., 2001) and humans
(Cote et al., 2007), may enhance CB1 activity and interfere with
glucose metabolism in muscle cells. Thus, it is conceivable that
activation of CB1 may down-regulate glucose uptake. Consis-
tently, either genetic silencing or pharmacological interference
up-regulates this function. However, whether SR141716 works
as an antagonist, by inhibiting constitutive CB1 activity in the
L6 cells, or as an inverse agonist, as largely recognized in other
cell types (Bouaboula et al., 1997, Xie et al., 2007), is currently
under investigation in our laboratories. It should be pointed out
that the SR141716 effect occurred in the absence of exogenous
anandamide and 2-arachidonoyl-glycerol, suggesting an inverse
agonist effect. However, autonomous cellular production of en-
docannabinoids cannot be excluded, also raising the possibility
of an antagonist effect of the compound. It is intriguing that
higher concentrations of the compound produced a paradoxical
decrease of 2-DG uptake. The latter effect is possibly due to the
partial agonist activity of SR141716 (De Vry and Jentzsch,
2004; Krylatov et al., 2005). One alternative explanation could
be found in the up-regulation of CB1 occurring at micromolar
concentrations of SR141716 in the L6 cells and in the primary
myocytes (data not shown). However, this effect is most proba-
bly a feature of cultured cell systems, and it may not occur “in
vivo” because of the drug turnover, mainly operated by liver
metabolism (Padwal and Majumdar, 2007).
As shown by protein expression profiling, the regulatory
effect of CB1 on glucose uptake is not due to changes in
cellular abundance of the main glucose transporters GLUT1
and GLUT4. The expression of major proteins involved in the
early events of insulin action on glucose uptake was also
Fig. 8. SR141716 increases PI3K signaling via PKA. A, cells were serum-
starved and incubated with LY294002 or with H-89, in the presence of 0.1
M SR141716 for 30 min or for 24 h, as described in the legend to Fig. 2
and under Materials and Methods. Then cell extracts were subjected to
SDS-PAGE followed by immunoblotting with specific anti phospho- or
control antibodies, as indicated. The autoradiographs shown are repre-
sentative of three independent experiments. B, filters obtained in A were
analyzed by laser densitometry as described under Materials and Meth-
ods. Asterisks indicate statistically significant differences (, p  0.01).
Fig. 9. SR141716 increases glucose uptake via PI3K and PKA. A, L6
myotubes were serum-starved and incubated with LY294002 or with
H-89 in the presence of 0.1 M SR141716 for 30 min or for 24 h. Then the
cells were assayed for 2-DG uptake as described under Materials and
Methods. Bars represent mean  S.D. of three different experiments in
triplicate (, p  0.001). B, primary myocytes were serum-starved for
24 h before exposure to 100 nM insulin for 30 min as indicated. On the
other hand, myocytes were incubated with LY294002 or with H-89 in the
presence of 0.1 M SR141716 for 30 min or for 24 h. Then the cells were
assayed for 2-DG uptake as described underMaterials andMethods. Bars
represent mean S.D. of three different experiments in triplicate (, p
0.01).
1684 Esposito et al.
unmodified upon CB1 pharmacological targeting. Several
lines of evidence indicate that CB1 regulation of glucose
uptake occurs through PI3K signaling. First, dose- and time-
dependent increases of both the regulatory (p85) and the
catalytic (p110) subunits were observed after treatment with
low concentrations of SR141716. Second, these effects were
paralleled by increased activity of several PI3K downstream
molecules (PDK1, PKC, and Akt/PKB). Third, the inhibition
of PI3K activity counteracted the effect of SR141716 on glu-
cose uptake.
It is noteworthy that the SR141716 effect occurred with
both short- (30 min) and long-term incubation. This is only
partially consistent with the timing of up-regulation of the
PI3K subunits by the CB1 antagonist compound.
The molecular events involved in both short- and long-term
CB1 regulation of PI3K require PKA activity. Indeed, in
parallel with p85 and p110 expression, SR141716 induces
increases in intracellular cAMP levels and CREB phosphor-
ylation at a PKA consensus site. H-89, a pharmacological
PKA blocker, inhibits both CREB phosphorylation and PI3K
signaling as well as SR141716-induced glucose uptake. It is
currently unknown whether CREB transcriptional activity is
involved in CB1-mediated regulation of glucose uptake. It
has been reported that CB1 is coupled to Gi/0 proteins
(Howlett et al., 1986). Then, engagement of CB1 by endoge-
nous ligands causes inhibition of adenylate cyclase and re-
duction of cellular cAMP levels (Bidaut-Russell et al., 1990).
SR141716 may uncouple CB1 from the inhibitory proteins
and increase cAMP levels, with a consequent activation of
PKA. PKA, in turn, regulates the expression of both p85 and
p110, at least in part, at the post-translational level as indi-
cated by the experiments in the presence of protein synthesis
inhibitors.
However, the rapid stimulatory effect of SR141716 on
PI3K activity and glucose uptake cannot be accounted for by
changes in the content of the PI3K subunits. CB1 modulation
therefore may also either directly activate PI3K, independent
of its expression, or regulate the activity of its downstream
targets (i.e., Akt). This is consistent with the potential role of
PKA to regulate PI3K activity in other cellular systems. It
has been described recently that PKA phosphorylates p85 on
Ser83 (Cosentino et al., 2007; De Gregorio et al., 2007). We
have now shown that SR141716 increases serine phosphor-
ylation of p85 in a PKA-dependent manner. Therefore, it
could be inferred that CB1 modulates PI3K by a dual mech-
anism: 1) a short-term mechanism, which directly stimulates
PI3K phosphorylation and activation, and 2) a long-term
mechanism, mediated by the enhanced PI3K expression.
Both effects are largely mediated by PKA activation.
Thus, at least in cultured cellular models, CB1 receptor
exerts an inhibitory action on glucose uptake, which could be
augmented by endocannabinoid stimulation. SR141716 re-
moves the inhibitory constraint maintained by CB1 tonic
activity and induces glucose uptake by cAMP/PKA- and
PI3K-mediated pathways. Genetic silencing of CB1 in skele-
tal muscle cells further supports this hypothesis. In conclu-
sion, beside antiobesity and antineoplastic effects (Van Gaal
et al., 2005; Pi-Sunyer et al., 2006; Sarnataro et al., 2006;
Bifulco et al., 2007), SR141716 may potentially possess a
glucoregulatory function, which is exerted at least in part by
direct regulation of glucose metabolism in skeletal muscle
cells.
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 Insulin-like Growth Factor-1 (IGF-1) 
signaling system exerts a broad anti-apoptotic 
function and plays a crucial role in resistance 
to anti-cancer therapies. Exposure of MCF-7 
breast cancer cells to IGF-1 rapidly and 
transiently induced tyrosine phosphorylation 
and activation of Phosphoinositide-
Dependent Kinase-1 (PDK1). This was 
paralleled by Akt/Protein Kinase B and 
Protein Kinase C-ζ  phosphorylation, at 
Thr308 and Thr410, respectively. IGF-1 
treatment also enhanced PDK1 interaction 
with IGF-1 receptor (IGF-1R) in intact MCF-
7 cells. Pull-down assays revealed that PDK1 
bound IGF-1R in vitro, and the region 
encompassing amino acids 51-359 of PDK1 
was necessary for the interaction. Synthetic 
peptides corresponding to IGF-1R C-
terminus amino acids 1295-1337 (C43) 
reduced in vitro IGF-1R/PDK1 interaction 
and PDK1 tyrosine phosphorylation by 
activated IGF-1R, in a concentration-
dependent manner. Similar peptides 
featuring replacement of Tyr1316 with 
phenylalanine were much less effective, 
however. Loading of fluoresceinated-C43 
(FITC-C43) into MCF-7 cells significantly 
reduced IGF-1R/PDK1 interaction and 
phosphorylation of PDK1 substrates. 
Moreover, FITC-C43 intracellular loading 
reverted the protective effect of IGF-1 on 
growth factor deprivation-induced cell death. 
Finally, the inhibition of IGF-1R/PDK1 
interaction and signalling by FITC-C43 was 
accompanied by 2-fold enhanced killing 
capacity of Cetuximab in human GEO colon 
adenocarcinoma cells and was sufficient to 
restore cell death in Cetuximab-resistant cell 
clones. Thus, disruption of PDK1 interaction 
with IGF-1R reduces IGF-1 survival effects in 
cancer cells and may enhance cell death by 
anti-cancer agents. 
 
INTRODUCTION 
 
The insulin-like growth factor (IGF) signalling 
system plays a key role in growth and 
development of many normal tissues and 
regulates overall growth of organisms (1). Type 
I insulin-like growth factor (IGF-1) has been 
identified as a regulator of cellular 
transformation and controls the acquisition of 
the tumorigenic phenotype by regulating 
multiple cellular functions that impact on the 
invasive/metastatic potential of cancer cells. 
These include cell survival, motility, invasion, 
growth potential in secondary organ sites, the 
induction of angiogenesis (2). There are also 
several lines of evidence that dysregulation of 
the IGF-1 system is involved in resistance to 
certain anticancer therapies, including cytotoxic 
chemotherapy, hormonal agents, biological 
therapies, and radiation (3). The link between 
cancer and IGF signalling is also consistent with 
recent epidemiological studies showing an 
increased relative risk for the development of 
colon, prostate, breast, lung, and bladder cancers 
in individuals with circulating IGF-1 levels in 
the upper tertile of the normal range (4). These 
findings were confirmed in animal models, 
where reduced circulating IGF-1 levels result in 
significant reductions in cancer development, 
growth, and metastases, whereas increased 
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circulating IGF-1 levels are associated with 
enhanced tumor growth (5).   
Aberrant expression of the receptor for IGF-1 
(IGF-1R) has been implicated in malignant 
transformation of cells (6, 7). IGF-1R is 
normally activated by binding of the secreted 
growth factor ligand to the extracellular domain. 
This, in turn, triggers a number of cellular 
signalling pathways, including the 
phosphatidylinositol 3-kinase (PI3K) pathway, 
the main mechanism by which IGF-1R protects 
cells from apoptosis (8, 9).  
Phosphoinositide-dependent protein kinase 1 
(PDK1) plays a crucial role in mediating signal 
transduction downstream of PI3K (10). PDK1 is 
a 64-kDa protein, of 556 amino acids, comprised 
of a serine/threonine kinase domain near the N-
terminus, a C-terminal pleckstrin homology 
(PH) domain, and an ATP-binding site located 
between the two domains (11). PDK1 
phosphorylates several protein kinases, including 
Akt/PKB and PKCs, at the activation loop 
phosphorylation sites (11-13). Phosphorylation 
of Ser241 at its own activation loop may be 
mediated by an intermolecular mechanism 
suggesting that dimerization and trans-
phosphorylation may regulate PDK1 activity in 
cells (10, 11, 14). There is also evidence that 
PDK1 undergoes tyrosine phosphorylation in 
response to several growth factors. Studies with 
the tyrosine phosphatase inhibitor pervanadate 
and insulin indicate that full activation of PDK1 
requires phosphorylation at Tyr373/376 (15-17). 
Consistent with its role in transformation, PDK1 
is highly expressed in a large number of invasive 
human breast cancer cell lines and in ovarian 
cancers (18, 19). 
Collectively, a large body of evidence identifies 
the IGF-1R/PDK1 system as a target for 
molecular therapy with potential benefits for a 
wide spectrum of human malignancies (3, 4, 20). 
Various strategies have been used to target 
components of this system in established cancer 
cell lines and animal models, and some of these 
strategies may be advancing to clinical use. 
Among them, down-regulation of IGF-1R by 
antisense oligonucleotides, antisense RNA, 
small interfering RNA, single chain antibody, 
full humanized anti-IGF-1R monoclonal 
antibodies and specific kinase inhibitors have 
been attempted (8, 21). Some of these molecular 
strategies to target the IGF-1 system, however, 
have failed for the magnitude of toxicity, due, at 
least in part,  to the cross reactivity with the 
insulin system. 
Here, we show that IGF-1R directly interacts 
with and activates PDK1. Synthetic peptides 
corresponding to the IGF-1R C-terminus 
selectively displace the interaction in vitro and 
reduce IGF-1 signalling via PDK1 in human 
cancer cell lines, preventing IGF-1 pro-survival 
effects and facilitating cell killing by anti-cancer 
agents. 
 
 
EXPERIMENTAL PROCEDURES 
 
Materials. Media, sera, and antibiotics for cell 
culture were from Invitrogen (Invitrogen 
Corporation, Paisley, United Kingdom). 
Antibodies against PDK1, IGF-1 Receptor α 
subunit,  IGF-1 Receptor β subunit, phospho-
Thr308 Akt1/PKB and Akt/PKBα were purchased 
from Upstate Biotechnology (Lake Placid, NY). 
PKCζ,  phospho-Thr410 PKCζ and extracellular 
signal-regulated kinases antibodies were from 
Santa Cruz Biotechnology (Santa Cruz, CA). 
Phospho-Ser473 Akt, phospho-Ser241 PDK1, 
Phospho-Tyr373/376 PDK1 and phospho-
Thr202/Tyr204 ERK were obtained from Cell 
Signaling Technology (Danvers, MA). 
Recombinant human IGF-1 was from PeproTech 
(London, UK). The p-EBG-2T expression vector 
containing the cDNA of the human full length 
PDK1 and the cDNA of PDK1 deletion mutants 
were a generous gift of Dr. D.R. Alessi 
(University of Dundee) and have been 
previously described (22). Protein A-Sepharose 
beads and enhanced chemiluminescence (ECL) 
reagents were from Pierce (Rockford, USA). 
Agarose-bound Wheat Germ Agglutinin (WGA) 
was from Vector (Vector Laboratories Inc., 
Burlingame, CA), sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
reagents from Bio-Rad (Richmond, VA). Nα-
protected Fmoc-amino acid derivatives and 
coupling reagents for peptide synthesis were 
from Inbios (Pozzuoli, Italy). HPLC-grade 
solvents and trifluoroacetic acid (TFA) were 
from LabScan (Stillorgan, Dublin, Ireland). All 
the other chemicals were from Sigma-Aldrich 
(St. Louis, MO).  
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Cell cultures. MCF-7 cells, L6 cells and NIH-
3T3 cells stably transfected with IGF-1 receptor 
(NIH-3T3IGF-1R) (23) were plated (6×103 
cells/cm2) and grown in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum and 2 mM glutamine, 
100 IU/ml penicillin, 100 IU/ml streptomycin. 
GEO and GEO-CR (24) colon cancer cells were 
cultured in McCoy's medium supplemented with 
10% fetal bovine serum, 20 mM Hepes (pH 7.4), 
2mM glutamine. Cultures were maintained in 
humidified atmosphere of 95% air and 5% CO2 
at 37 C. L6 differentiation has been achieved as 
previously described (Caruso et al., 1997). 
 
 
Immunoblot and Immunoprecipitation 
Procedure. Cells were solubilized for 20 min at 
4C with lysis buffer containing 50 mM HEPES, 
150 mM NaCl, 10 mM EDTA, 10 mM Na4P2O7, 
2 mM sodium orthovanadate, 50 mM NaF, 1 
mM phenylmethylsulfonyl fluoride, 10 µg/ml 
aprotinin, 10 µg/ml leupeptin, pH 7.4, and 1% 
(v/v) Triton X-100. The lysates were clarified by 
centrifugation at 12,000g for 20 min at 4C. 
Proteins were separated by SDS-polyacrylamide 
gel electrophoresis and blotted on Immobilon-P 
membranes (Millipore, Billerica, MA). 
Membranes were blocked for 1 h in TBS (10 
mM Tris-HCl, pH 7.4, and 140 mM NaCl) 
containing 4% (w/v) bovine serum albumin and 
then incubated with the indicated antibodies. 
Detection of blotted proteins was performed by 
ECL according to the manufacturer's instruction. 
Immunoprecipitation experiments were 
performed as previously described (25). 
Densitometric analysis was performed using a 
Scion Image Analyzer. All the data were 
expressed as mean ± SD. Significance was 
assessed by Student’s t test for comparison 
between two means. Data were analyzed with 
Statview software (Abacusconcepts) by one-
factor analysis of variance. P values of less than 
0.05 were considered statistically significant. 
 
IGF-1 receptor purification. IGF-1R were 
partially purified by WGA affinity 
chromatography. Confluent monolayers of NIH-
3T3IGF-1R cells (corresponding to 6-8 x 107 cells) 
were solubilized in lysis buffer. The insoluble 
material was separated by ultracentrifugation at 
100,000 x g for 1 h at 4 C. The supernatant was 
applied to a WGA-Sepharose column pre-
equilibrated with HNT buffer (50 mM HEPES, 
150 mM NaCl and 0.1% Triton) and the protease 
inhibitors described above. The column was 
extensively washed using the same buffer, and 
bound glycoproteins were eluted in the same 
buffer containing 0.3 M N-acetylglucosamine 
(26).  
 
Pull down assay. PDK1-glutatione S-transferase 
(GST) fusion proteins were generated as 
described (22). Purified IGF-1R (50 µg protein 
extract) was incubated in the presence of 
Sepharose-bound GST-PDK1 (2 µg) for 2 h at 4 
C. The beads were washed two times with HNT 
buffer, then resuspended in loading buffer, 
heated to 95 C for 5 min and centrifuged at 
25,000 x g for 3 min. Supernatants were 
separated by SDS-PAGE followed by 
immunoblotting with appropriate antibodies. 
 
In vitro PDK1 tyrosine phosphorylation. 
Purified IGF-1R (50 µg protein extract) was 
incubated in the presence of IGF-1 (100 ng/ml). 
Phosphorylation reactions were initiated by 
adding 2 mM CTP, 2 µM ATP, 10 mM HEPES, 
pH 7.4, 0.02% Triton X-100, 5 mM MnCl2, 7 
mM MgCl2 (final concentrations) and prolonged 
for 30 min at 22 C. Recombinant PDK1 was 
added for 15 min. The reaction was stopped on 
ice and proteins were separated by SDS-PAGE 
and analyzed by Western blotting with 
phosphotyrosine antibodies. 
 
Peptide synthesis and purification. Solid-phase 
peptide syntheses were carried out on a fully 
automated peptide synthesizer 433A (Applied 
Biosystems). Preparative RP-HPLC purifications 
were carried out on a Shimadzu LC-8A 
instrument, equipped with a SPD-M10 AV 
detector and using a Phenomenex Luna-COMBI 
C18 column (50x22 mm ID; 10 µm). LC-MS 
analyses were carried out on an LCQ DECA XP 
Ion Trap mass spectrometer (ThermoElectron, 
Milan, Italy) equipped with an OPTON ESI 
source, operating at 4.2 kV needle voltage and 
320 C and with a complete Surveyor HPLC 
system. LC-MS columns were from 
ThermoElectron. Peptides were prepared by 
solid phase synthesis following standard 
Fmoc/tBu protocols (27). To monitor cell 
delivery, N-terminal fluoresceine labelling was 
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achieved by on-resin treatment with fluorescein 
isothiocyanate (FITC). Cleavage from the solid 
support was performed by treatment with a 
trifluoroacetic acid (TFA)/tri-isopropyl-silane 
(TIS)/water (90:5:5, v/v/v) mixture for 90 min at 
RT, then crude peptides were precipitated in 
cold ether, dissolved in a water/acetonitrile (1:1, 
v/v) mixture and lyophilized. Products were 
purified by RP-HPLC applying a linear gradient 
of CH3CN, 0.1% TFA (Solvent B) from 5% to 
65% over 40 min. Solvent A was 0.1% TFA in 
water. Flow rate was 20 ml/min. Peptides purity 
and identity were confirmed by LC-MS. 
 
Peptide loading into cultured cells. Peptides 
were delivered onto MCF-7 cells by using the 
ProVectin Protein delivery reagents method 
according to the manufacture’s instructions. 
Briefly, the dry film of ProVectin reagent found 
in glass vial was dissolved with 250 µl of 
methanol and vortexed for 10-20 seconds. 20 µl 
of ProVectin reagent for a 60-mm-diameter 
dishes were recommend. The total amount of 
ProVectin needed was pipetted into an 
eppendorf tube and left under a laminar flow 
hood to evaporate the solvent for at least 2 hours 
at room temperature and then hydrated with 
PBS. Peptides, diluted in PBS, were added to 
ProVectin reagent at different concentrations and 
let stand at room temperature for 5 min. The 
ProVectin/peptide complexes were added 
directly onto the cells cultured in serum-free 
DMEM for 24 h. 
 
Cell death analysis. For detecting apoptosis, the 
cells were kept in the presence or in the absence 
of serum or incubated with 10 mM synthetic 
peptides, as indicated in the description of the 
individual experiments. Apoptosis was then 
assayed using the Apoptosis ELISA Plus kit 
(Roche Diagnostics GmbH, Mannheim, 
Germany), according to the manifacturer’s 
instructions or by cytometric analysis. Briefly,  
cells were harvested and suspended in 0.3 ml of 
PBS. After adding 0.7 ml of cold absolute 
ethanol, cells were fixed and stored for at least 2 
h at –20 C. For analysis, cells were centrifuged, 
resuspended in PBS containing 0.1mg/ml 
RNaseA and 40 µg/ml propidium iodide and 
incubated in dark for 30 min at room 
temperature. Samples were kept on ice and the 
analysis was performed using FACS Cyan 
cytometer (Dako Cytomation, USA). A 
minimum of 30000 events were collected for 
each sample. Sub-G1 phase cells were identified 
using Summit V 4.3 software (Dako). 
 
Fluorescence microscopy. Cells, loaded with 
FITC-peptides, were fixed with 3% 
formaldehyde for 15 min at 37 C, washed three 
times with PBS and incubated for 10 min at RT 
with DAPI diluted 1: 1000 in TBS. All slides 
were then washed three times with TBS 0.1% 
Tween and kept in dark until examined under a 
fluorescence microscope. 
 
2-Deoxy-D-glucose Uptake. The measurement of 
2-deoxy-D-[14C] glucose uptake was taken as a 
readout of glucose uptake by muscle cells, as 
previously described (Klip et al., 1982). Cells 
were incubated in serum free DMEM 
supplemented with 0.2% (w/v) bovine serum 
albumin for 18 h in the presence or absence of 
C43 or SP 10 µM. Cells were incubated in 
glucose-free 20 mM HEPES, pH 7.4, 140 mM 
NaCl, 2.5 mM MgSO4, 5 mM KCl, 1 mM 
CaCl2 (HEPES buffer) and exposed or not to 
100 nM insulin for 30 min. Glucose uptake was 
measured by incubating cells with 0.15 mM 2-
deoxy-D-[14C]glucose (0.5µCi/assay) for 15 min 
in HEPES buffer. The reaction was terminated 
by the addition of 10 µM cytochalasin B, and the 
cells were washed three times with ice-cold 
isotonic saline solution prior to lysis in 1 M 
NaOH. Incorporated radioactivity was measured 
in a liquid scintillation counter. 
 
 
RESULTS 
 
IGF-1 induces PDK1 tyrosine 
phosphorylation and co-precipitation with 
IGF-1R in MCF-7 cells. We analyzed tyrosine 
phosphorylation of PDK1 in response to IGF-1 
in human breast cancer cells. MCF-7 cells were 
incubated with serum-free medium and treated 
with IGF-1 (100 ng/ml) for 5 and 30 min. 
Western blot analysis with antibodies 
specifically recognizing pTyr373/376-PDK1, 
revealed that IGF-1 rapidly induces tyrosine 
phosphorylation of endogenous PDK1, 
compared to the control cells. Tyrosine 
phosphorylation returned close to the basal 
levels after 30 min, with no change in the total 
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PDK1 levels (Fig. 1A). To gain further insights 
into the molecular mechanism of PDK1 
phosphorylation, we tested the ability of IGF-1R 
to interact with PDK1. To this aim, MCF-7 cells 
were stimulated with IGF-1 (100ng/ml) and cell 
lysates were precipitated with IGF-1R antibodies 
followed by blotting with PDK1 antibodies. As 
shown in Fig. 1B, an interaction between IGF-
1R and PDK1 occurred after 5 min of IGF-1 
exposure while, as in the case of tyrosine 
phosphorylation, the interaction was poorly 
detectable after 30 min. Immunoblotting with 
specific antibodies also revealed that IGF-1R-
associated PDK1 was phosphorylated at Ser241 
(Fig. 1B). Moreover, stimulation of MCF-7 cells 
with IGF-1 increased phosphorylation of 
Akt/PKB and PKCζ, at the PDK1 consensus 
sites, indicating the induction of PDK1 activity. 
Control detection with Akt/PKB and 
PKCζ antibodies revealed no difference in the 
total levels (Fig.1C). 
 
IGF-1R directly interacts with and 
phosphorylates PDK1 in vitro. In order to 
determine the PDK1 portion involved in the 
interaction with IGF-1R,  recombinant GST 
fused with full-length PDK1 protein (residues 1-
556), two PDK1 mutants lacking the PH domain 
(corresponding to residues 1-359 and 51-359, 
respectively), and the PH domain alone (residues 
408-556) were used in pull-down experiments 
with purified IGF-1R. IGF-1R was detectable in 
GST-pull down experiments with the full length 
PDK1. The interaction was also well detectable 
for PDK151-359 and PDK11-359, while it was 
almost completely absent with PDK1408-556 (Fig. 
2A).  
It has been previously reported (17) that the 
region corresponding to the insulin receptor (IR) 
C-terminus is critical for the interaction with 
PDK1. With this background, peptides 
corresponding to the C-terminal residues 1295-
1337 of IGF-1R (C43), 1316-1337 (C22) and 
similar peptides featuring tyrosine replacement 
with phenylalanine (C43F and C22F) were 
synthesized (Fig. 2B). In pull-down assays (Fig. 
2C), C43 peptide displayed the highest ability to 
reduce IGF-1R/PDK1 interaction (ED50 = 80 
nM). At variance C43F (ED50 =  1 µM), C22 
(ED50 >1 µM) and C22F (ED50 >1 µM) were 
significantly less effective (Fig. 2C). 
Furthermore, a synthetic peptide corresponding 
to the IR C-terminus (C-IR) and a scrambled 
peptide (SP) did not significantly impair IGF-
1R/PDK1 interaction (Fig. 2C). Similarly, co-
incubation with C43 reduced tyrosine 
phosphorylation of PDK1 by activated IGF-1R 
in a concentration-dependent manner (Fig. 2D).  
 
IGF-1R C-terminus peptides reduce PDK1 
signalling and prevent IGF-1 protection from 
apoptosis in MCF-7 cells. In order to evaluate 
the ability to reduce IGF-1R/PDK1 interaction in 
intact cells, C43 was conjugated to fluorescein 
isothiocyanate (FITC-C43) and loaded into 
MCF-7 cells at different concentrations (range: 
100 nM – 10 µM). Peptide loading was 
confirmed by FACS analysis (Fig. 3A) and 
fluorescence microscopy (Fig. 3B). Next, MCF-
7 cells were loaded with 10 µM FITC-C43 and 
stimulated for 5 min with 100 ng/ml IGF-1. As 
shown in Fig. 4A, peptide loading decreased 
IGF-1R/PDK1 co-precipitation in response to 
IGF-1, as compared to a scrambled peptide 
(FITC-SP). Consistently, FITC-C43 loading was 
paralleled by reduced Akt/PKB and PKCζ 
phosphorylation in response to IGF-1 (Fig. 4B 
and 4C). ERK1/2 phosphorylation was 
preserved, instead.  
In the MCF-7 cells, exposure to IGF-1 for 16 h 
rescued cell death induced by growth factor 
deprivation (Fig. 5A and 5B). Therefore, we 
wanted to prove the principle that IGF-1 
protective effect on cell death could be reverted 
by disrupting the interaction between IGF-1R 
and PDK1. To this aim, 10µM FITC-peptides 
(C43, C43F, C22, C22F and C-IR) were loaded 
into MCF-7 cells before the treatment with IGF-
1. Interestingly, loading of C43 completely 
reverted IGF1 protective action, while no 
significant effect was elicited by the other 
peptides (Fig. 5A and 5B). 
 
Effect of C43 on glucose uptake in L6 cells. In 
order to investigate whether reduced IGF-
1R/PDK1 interaction  may affect glucose uptake 
in a skeletal muscle cell model we have 
performed a 2-deoxy-glucose (2-DG) uptake 
assay in L6 cells in the absence or in the 
presence of 10 µM of C43 or SP (Fig. 5C). No 
significant effect was achieved following 
treatment of L6 cells with C43 or SP (Fig. 5C). 
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Synergic effect of C43 and Cetuximab on 
GEO and GEO-CR cells. It has been shown 
that switching to the IGF-1R pathway is a 
common mechanism to promote resistance to 
anti-EGFR treatment (28). The correlation 
between IGF-1R activation and acquired 
resistance to EGFR inhibitors has been 
demonstrated for several cancer cell lines (29). 
Therefore, we investigated whether C43 could 
affect the response to Cetuximab (C225) in 
human colon adenocarcinoma cells (GEO cells) 
and in a clone of GEO cells resistant to 
Cetuximab action (GEO-CR). FITC-C43 or 
FITC-SP (10 µM) were loaded into GEO and 
GEO-CR and the entry was assessed by FACS 
and fluorescence microscopy (data not shown). 
In GEO cells, C225 increased cell death by 1,5-
fold. FITC-C43 loading did not significantly 
change basal cell death, compared to the control, 
but enhanced the effect of C225 up to 2-fold 
(Fig. 6). As expected, C225 was ineffective in 
GEO-CR cells. However, when FITC-C43 was 
loaded into the cells, C225 effect was detectable 
at levels similar to those observed in GEO cells. 
No effect was elicited when FITC-SP was 
loaded in the cells (Fig. 6). 
Next, we  analyzed the effect of C43 on IGF-1 
signalling in GEO and GEO-CR cells. IGF-1R 
total content and tyrosine phosphorylation were 
unchanged by the peptide (data not shown). In 
both cell lines FITC-C43 loading decreased IGF-
1-induced PDK1 tyrosine phosphorylation (Fig. 
7A) and IGF-1R co-precipitation (Fig. 7B), 
while no effect was elicited by FITC-SP. We 
also analyzed Akt/PKB phosphorylation, as a 
marker for PDK1 activity. As shown in Fig. 6C, 
FITC-C43, but not FITC-SP, reduced Akt/PKB 
phosphorylation in response to IGF-1, both in 
GEO and GEO-CR cells. Nevertheless, upon 
FITC-C43 loading, IGF-1-induced ERK1/2 
phosphorylation was preserved in GEO cells, but 
reduced in GEO-CR cells (Fig. 7C). 
 
DISCUSSION 
 
Targeting IGF-1R signalling pathways 
represents an attractive strategy for innovative 
therapeutic approaches (3, 30-32). Therefore, 
understanding the details of IGF-1R signalling 
may be beneficial to envision tailored strategies. 
We have described that upon ligand binding, 
IGF-1R directly interacts with and 
phosphorylates PDK1 at Tyr373/376. The 
molecular interaction may account, at least in 
part for the specificity of IGF-1 signals via 
PDK1. Indeed, recruitment of kinases in close 
proximity of specific ligand-receptor complexes 
may selectively direct their further action (12). 
The interaction between PDK1 and IGF-1R 
requires residues 51-359 of PDK-1, and not the 
PH domain (aa 408-556), which is located at the 
C-terminus of the molecule. However, the 
substrate tyrosines are distal to the former 
portion. Thus, one may hypothesize that the PH 
domain of PDK1 binds to plasma membrane 
lipids (33, 34), and the N-terminal portion 
interacts with the IGF-1R β-subunit, thereby 
locating the tyrosines in proximity of IGF-1R 
catalytic domain. IGF-1R C-terminal residues 
are likely involved in PDK1 binding. Indeed, in 
vitro, a synthetic peptide corresponding to the 
IGF-1R C-terminus (residues 1295-1337; C43) 
inhibits the interaction between the two 
molecules.  
This hypothesis is further supported by the 
finding that intracellular loading of C43 peptide 
prevents co-precipitation of PDK1 with IGF-1R 
antibodies, both in MCF-7, breast cancer, and in 
GEO, colon cancer cells. Moreover, C43 loading 
in intact cells reduced IGF-1-stimulated 
phosphorylation of the PDK1 substrates 
Akt/PKB and PKCζ, suggesting that either 
interaction with IGF-1R or tyrosine 
phosphorylation are needed for eliciting 
downstream effects. Similarly, C43 loading is 
sufficient to impair IGF-1 anti-apoptotic effect. 
This is consistent with previous findings 
indicating that PI3K activation is a relevant 
mechanism for IGF-1-mediated cell survival 
(35). This is also consistent with previous work 
by Baserga and LeRoith groups, demonstrating 
that the C-terminus portion is required for the 
transforming potential of the IGF-1R (36). In 
addition, a peptide bearing substitution of Tyr1316 
with a phenylalanine (C43F) failed to be as 
effective as the wild-type C43. These 
observations suggest that Tyr1316 is necessary for 
the interaction with PDK1. However, neither a 
similar peptide, corresponding to the insulin 
receptor C-terminus (containing a tyrosine in a 
similar position), nor shorter peptides containing 
or not Tyr1316 (residues 1316-1337; C22, C22F), 
were able to elicit comparable effects. 
Noteworthy, the  upper segment of C43 
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(residues 1295-1316) displayed weaker 
homology with the corresponding IR fragment, 
compared to the  lower segment (see Fig. 2B)  
Thus, one might speculate that the specificity of 
interaction resides in the amino acid stretch 
immediately upstream Tyr1316.  
Reiss et al.  reported that a peptide 
encompassing residues 1282-1298 (peptide 2) 
induces apoptosis in mouse embryo fibroblasts, 
with minor changes in IGF-1 signalling, 
suggesting that peptide 2 per se could elicit the 
activation of caspase cascade (37). While we 
cannot exclude the possibility that C43 may 
directly impinge on the caspase pathway as well, 
our in vitro data indicate that the main 
mechanism could be related to its ability to 
interfere with IGF-1R/PDK1 interaction. 
Nevertheless, the other peptides at the 
concentration used (10 µM) slightly increased 
apoptosis in the absence of alterations in IGF-1 
signalling, further exploiting the concept that the 
C-terminus fragment of the IGF-1R may possess 
an intrinsic pro-apoptotic function (38, 39). 
Previous findings indicated that IGF-1 alters 
sensitivity to several anticancer drugs by 
inhibiting apoptosis (40). More recent evidence 
also points to IGF-1 as a major candidate for the 
acquired resistance to tyrosine kinase inhibitors 
and monoclonal antibodies as cancer 
therapeutics (41, 42). Up-regulation of IGF-1 or 
IGF-1R (43), down-regulation of IGF-binding 
proteins (44), heterodimerization of the IGF-1R 
with other tyrosine kinase receptors (28, 45) are 
putative mechanisms accounting for drug 
resistance. On the other hand, the use of mAbs 
or inhibitors of IGF-1R tyrosine kinase, although 
effective in a number of human tumors (46), 
have encountered difficulties, at least in part, 
because of the cross-interference with insulin 
receptor signalling (47). One of the potential 
mechanisms involves the signalling through 
PDK1 by both pathways. 
Indeed, PDK1 beside being a potential molecular 
target for cancer therapy (20) is largely involved 
in the control of glucose metabolism. 
Pharmacologic or genetic blockade of PDK1 
enhances apoptosis but severely affects glucose 
metabolism in animal models (48, 49). 
Moreover, 7-Hydroxystaurosporine (UCN-01), a 
non-selective inhibitor of PDK1, has shown anti-
apoptotic activity in cancer cells (50) and has 
been tested in Phase I trials (51, 52). Although 
displaying an acceptable toxicity profile, 
hyperglycaemia is a relevant adverse event, 
possibly due to the major role exerted by PDK1 
in regulation of insulin-stimulated glucose 
metabolism (51). We now show that pathway-
selective strategies may help to discriminate 
between IGF-1R and IR signalling via 
PI3K/PDK1. In this regard, C43 loading into L6 
skeletal muscle cells does not significantly 
inhibit insulin-stimulated glucose uptake (Fig. 
5C). 
Disrupting communication between IGF-1R and 
PDK1, by means of C43, is sufficient to prevent 
IGF-1 protection from apoptosis induced by 
growth factor deprivation. In addition, C43 
exposure of GEO cells enhanced cell death 
following treatment with cetuximab and, 
importantly, restored cell killing in cetuximab-
resistant clones. It has been recently suggested 
that combined inhibition of IGF-1 signals, which 
mainly occurs via PI3K, and EGF signals, 
mainly via ERK, results in a synergistic effect in 
colon cancer cells (53). We now observe that 
targeting IGF-1R C-terminus in a cetuximab-
resistant clone of colon cancer cells,  although 
per se not sufficient to induce cell death, blocked 
both PDK1 and ERK1/2 activation and restored 
sensitivity to cetuximab, supporting the 
hypothesis that both pathways are needed to 
escape cell death. The mechanism by which C43 
may also interfere with ERK activation remains 
to be elucidated. Since no hyper-
expression/hyper-activation of IGF-1 signalling 
components has been detected in GEO-CR cells, 
IGF-1R/EGFR hybrid formation could explain 
the differential impairment of the ERK pathway 
by C43. This is a less likely possibility, however, 
since C43 failed to inhibit EGF signalling in 
both GEO and GEO-CR cells (data not shown). 
Alternatively, as also described in other cell 
types (54), PDK1 may directly regulate 
MEK/ERK pathway. Whether and how this 
occurs in GEO-CR and not in GEO cells, 
however remains unclear. In addition, in drug 
resistant cells, IGF-1R may have acquired the 
ability through its C-terminus to recruit different 
signalling complexes, finally leading to ERK1/2 
activation (55). 
Thus, we have provided the proof of principle 
that targeted disruption of IGF-1R/PDK1 
interaction prevents anti-apoptotic action of IGF-
1 and may facilitate cell killing by anticancer 
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agents. Moreover, selectively interfering with 
IGF-1R signalling restores cell death in 
cetuximab resistant colon cancer cells. 
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FIGURE LEGENDS 
 
Figure 1. PDK1 tyrosine phosphorylation, IGF-1R co-precipitation and substrate 
phosphorylation. A) MCF-7 cells were exposed to 100 ng/ml IGF-1 for 5 and 30 min, as indicated, 
and then solubilized as described in Experimental Procedures. Cell lysates (50 µg protein/sample) 
were blotted with phospho-tyrosine-373/376-PDK1 antibodies (pTyr373/376-PDK1). To ensure the 
equal PDK1 transfer, membranes were blotted with PDK1 antibodies (PDK1). The filters were 
revealed by ECL and autoradiography. B) MCF-7 cell  lysates (200µg/sample) were 
immunoprecipitated with IGF-1R α-subunit antibodies, followed by blotting with PDK1 antibodies 
and then re-blotted with phospho-serine-241-PDK1 antibodies (pSer241-PDK1). To ensure equal 
immunoprecipitation, membranes were blotted with α-subunit-IGF-1R antibodies (α−sub-IGF-1R). 
Membranes were revealed by ECL and autoradiography. C) MCF-7 total cell lysates (50 µg 
protein/sample) were blotted with phospho-threonine-308-Akt/PKB (pThr308-Akt/PKB) and phospho-
threonine-410-PKCζ (pThr410-PKCζ) antibodies and then re-blotted with Akt/PKB and 
PKCζ  antibodies. Membranes were revealed by ECL and autoradiography. 
The autoradiographs shown are representative of four independent experiments. 
 
Figure 2. In vitro interaction of IGF-1R with PDK1. A) IGF-1R was partially purified from 
NIH3T3IGF-1R by WGA affinity chromatography and subjected to pull-down using full length GST-
PDK1 and deletion mutants (aa 1-359, aa 51-359 and aa 408-556). Equal amounts of IGF-1R were 
incubated with each fusion protein, then eluted and analyzed by 7,5% SDS-PAGE; IGF-1R bound to 
fusion proteins was detected by Western blotting using anti-β subunit IGF-1R antibodies. B) Amino 
acid sequence alignment of synthetic peptides corresponding to IGF-1R C-terminus fragment (C43; 
C22), to a mutated version, in which Tyr1316 has been substituted with Phe (C43F; C22F), and to 
insulin receptor C-terminus (C-IR).  C) Partially purified IGF-1R was incubated for 2 h at 4 C with 
Sepharose-GST-PDK1, in the presence or in the absence of synthetic peptides (C43, C43F, C22, 
C22F,  C-IR and SP) at increasing concentration as indicated. Pulled-down proteins were blotted with 
anti IGF-1R (β subunit) antibody and the results quantitated by laser densitometry. D) Equal amounts 
of purified IGF-1R were stimulated with 100 ng/ml IGF1, as described in Materials and Methods, and 
incubated with GST-PDK1 in the presence of increasing concentrations of C43, as indicated. Proteins 
were blotted with pTyr373/376-PDK1 antibodies. Membranes were re-blotted with PDK1 and IGF-1R 
(α subunit) antibodies, as shown on the bottom. Blots were revealed by ECL and autoradiography.  
The autoradiographs shown are representative of at least four independent experiments. 
 
Figure 3. Transduction of FITC-C43 into MCF-7 cells. A). MCF-7 cells were incubated with 
increasing concentrations of the fluoresceine-conjugated peptide (FITC-C43), as indicated. Peptide 
uptake in MCF7 cells was detected by FACS analysis of fluorescein-labelled cells. B) MCF-7 cells 
were incubated with FITC-C43 peptide (10 µM) and fixed in formaldehyde at 37 C. Uptake and 
intracellular distribution were monitored by fluorescence with appropriate filters. Panel I  shows the 
FITC-C43 peptide internalized in the cells with prevalent sub-membrane localization;  panel II  shows 
cell nuclei stained with DAPI reagent, panel III shows the overlay… 
These experiments were repeated three times with similar findings. 
 
Figure 4. Effect of C43 on IGF-1 signalling in intact MCF-7cells. A) MCF-7 cells, treated with 
FITC-Scrambled Peptide (FITC-SP) or with FITC-C43, were starved for 16 h and stimulated for 
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indicated time with 100 ng/ml IGF-1. Cell lysates (200µg/sample) were immunoprecipitated with anti 
IGF-1R (α sub) antibody, then immunoprecipitated proteins were separated on SDS-PAGE and 
Western blot analysis was performed with anti PDK1 and anti IGF-1R α subunit antibodies. Blots 
were revealed by ECL and autoradiography. B) MCF-7 cells, loaded with FITC-SP or FITC-C43, 
were incubated for 5 min with 100 ng/ml IGF-1. Total cell lysates (50µg protein/sample) were blotted 
with pThr308-Akt/PKB or pThr410-PKCζ or phospho-Threonine-202/Tyrosine-204-ERK1/2 (pERK) 
antibodies and then re-blotted with Akt/PKB,  PKCζ or ERK1/2 antibodies. Membranes were 
revealed by ECL and autoradiography. The autoradiographs shown are representative of four 
independent experiments. C) Filters obtained in B have been analyzed by laser densitometry as 
described in Experimental Procedures. Asterisks indicate statistically significant differences (***, 
p<0.001). 
 
Figure 5. Biological effect of reduced IGF-1R/PDK1 interaction  in intact cells. A) MCF-7 cells, 
loaded with FITC-C43, -C43F, -C22, -C22F , -C-IR or SP, were incubated in serum-free DMEM for 
16 h in the presence or in the absence of IGF-1and apoptosis was quantified by the ELISA plus 
apoptosis detection kit as described under Experimental Procedures.B) MCF-7 cells, loaded 
with FITC-C43, -C43F, -C22, -C22F ,-C-IR or SP, were incubated in serum-free DMEM for 16 h in 
the presence or in the absence of IGF-1. Cells were stained with propidium iodide and ratio of cells in 
sub-G1 phase was determined by cytometric analysis, as described in Experimental Procedures. C) L6 
cells were incubated in serum-free media for 16 h before exposure to 100 nM insulin for 30 min, as 
indicated. Alternatively, 10 µM of C43 or SP were simultaneously added to serum-free media in the 
presence or absence of insulin. Then the cells were assayed for 2-DG uptake as described in 
Experimental Procedures. Bars represent mean ± S.D. of three different experiments in triplicate. 
Asterisks indicate statistically significant differences vs untreated cells (***, p<0.001). 
 
  
Figure 6. Synergistic effect of C43 and Cetuximab on GEO and GEO-CR cells. 10 µM FITC-C43 
or FITC-SP was loaded into GEO and GEO-CR cells. After 24 h treatment with Cetuximab (C225), 
the cells were harvested, fixed and stained with propidium iodide. The ratio of cells in sub-G1 phase 
was determined by cytometric analysis, as described in Experimental Procedures. 
 
Figure 7. Effect of C43 on IGF-1 signalling in GEO and GEO-CR cells. A) GEO and GEO-CR 
cells, treated with FITC-SP or FITC-C43, were exposed to 100 ng/ml IGF-1, as indicated, and then 
solubilized. Cell lysates (50 µg protein/sample) were blotted with pTyr373/376-PDK1 antibody. To 
ensure equal PDK1 transfer, membranes were further blotted with PDK1 antibodies. Blots were 
revealed by ECL and autoradiography. B) GEO and GEO-CR cells were loaded with FITC-SP or with 
FITC-C43 and then stimulated for indicated time with 100 ng/ml IGF-1. Cell lysates (200 µg/sample) 
were immunoprecipitated with anti IGF-1R (α sub) antibody, then immunoprecipitated proteins were 
separated on SDS-PAGE. Western Blot analysis was performed with anti PDK1 and anti IGF-1R β 
subunit antibodies. Blots were revealed by ECL and autoradiography. C) GEO and GEO-CR cells, 
loaded with FITC-SP or with FITC-C43 were stimulated with 100 ng/ml IGF-1 and then solubilized 
as described in Material and Methods. Total cell lysates (50 µg protein/sample) were blotted with 
pThr308-Akt/PKB or pERK antibodies and then re-blotted with Akt/PKB or ERK1/2 antibodies. 
Membranes were revealed by ECL and autoradiography.  
The autoradiographs shown are representative of four independent experiments. 
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